I. Introduction
   A. Historical perspective
   B. Nomenclature
II. Ultrastructure and Morphological Features
   A. Ultrastructure
   B. Retinoid storage
III. Origin and Cytoskeletal Phenotype of Stellate Cells
   A. Embryologic origin(s)
   B. Heterogeneity and plasticity of hepatic stellate cells
   C. Extrahepatic stellate cells
IV. Models and Methods of Characterizing Stellate Cells
   A. Cell isolation methods
   B. Cell lines
   C. Effects of matrix and culture conditions
   D. Other models: liver slices, in vivo methods
V. Functions of Hepatic Stellate Cells in Normal Liver
   A. Role in liver development and regeneration
   B. Retinoid metabolism
   C. Immunoregulation
   D. Secretion of lipoproteins, growth factors, and cytokines
   E. Biology of membrane and nuclear receptors
   F. Adipogenic features
   G. Detoxifying and antioxidant enzymes, pH regulation, and generation of oxidant stress
   H. Transcriptome and proteome analyses
VI. Stellate Cell Responses in Liver Injury and Repair
   A. Stellate cell activation: features, regulation, and reversibility
   B. Transcriptional regulation of stellate cell behavior
   C. Paracrine interactions with other resident liver cells
   D. Behavior of stellate cells in liver disease
VII. Unanswered Questions and Future Directions

Friedman SL. Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver. Physiol Rev 88: 125-172, 2008; doi:10.1152/physrev.00013.2007.—The hepatic stellate cell has surprised and engaged physiologists, pathologists, and hepatologists for over 130 years, yet clear evidence of its role in hepatic injury and fibrosis only emerged following the refinement of methods for its isolation and characterization. The paradigm in liver injury of activation of quiescent vitamin A-rich stellate cells into proliferative, contractile, and fibrogenic myofibroblasts has launched an era of astonishing progress in understanding the mechanistic basis of hepatic fibrosis progression and regression. But this simple paradigm has now yielded to a remarkably broad appreciation of the cell’s functions not only in liver injury, but also in hepatic development, regeneration, xenobiotic responses, intermediary metabolism, and immunoregulation. Among the most exciting prospects is that stellate cells are essential for hepatic progenitor cell amplification and differentiation. Equally intriguing is the remarkable plasticity of stellate cells, not only in their variable intermediate filament phenotype, but also in their functions. Stellate cells can be viewed as the nexus in a complex sinusoidal milieu that requires tightly regulated autocrine and paracrine cross-talk, rapid responses to evolving extracellular matrix content, and exquisite responsiveness to the metabolic needs imposed by liver growth and repair. Moreover, roles vital to systemic homeostasis include their storage and mobilization of retinoids, their emerging capacity for antigen presentation and induction of tolerance, as well as their emerging relationship to bone marrow-derived cells. As interest in this cell type intensifies, more surprises and mysteries are sure to unfold that will ultimately benefit our understanding of liver physiology and the diagnosis and treatment of liver disease.
I. INTRODUCTION

The hepatic stellate cell, first described by Kupffer in the 19th century, has emerged in the past 25 years as a remarkably versatile mesenchymal cell that is vital to hepatocellular function and the liver’s response to injury. Indeed, the paradigm of stellate cell activation into contractile myofibroblasts as the major pathway in hepatic fibrogenesis associated with liver injury has dominated the focus of studies on this fascinating cell type. Beyond this well-known role, however, a broad range of newly discovered activities, some of which are entirely unexpected, have ignited mounting interest and led to a greater understanding of the complexity of cellular homeostasis in liver. Progress in this area has accelerated as a result of greatly refined methods of cellular isolation, sophisticated genetic models of disease, and improved tools of analysis, including flow cytometry, quantitative real-time PCR, confocal imaging, and molecular markers of cellular origin and phenotype. As a result, the number of related publications has grown dramatically (Fig. 1).

Countless studies have explored the importance of hepatic stellate cells in liver fibrosis and repair, but a more comprehensive review article about this cell type, apart from its role in fibrosis, has been lacking for at least a decade. Thus this review will primarily highlight the tremendous breadth of new knowledge about the features of the stellate cell and its functions and responses in all aspects of liver function, rather than emphasizing only its role in fibrosis, for which several recent reviews are recommended (35, 165, 167, 213, 263, 313, 363).

A. Historical Perspective

Kupffer’s initial description of stellate cells was made in 1876, using a gold chloride method that identifies vitamin A-containing droplets (678). Referring to these cells as “sternzellen” (“star cells” in German) (24, 677), their identity was later confirmed by Rothe (1882) (677). Kupffer’s initial observations failed to distinguish stellate cells from resident hepatic macrophages (now referred to as “Kupffer cells”), however, leading to some confusion about whether sternzellen were phagocytic, a property normally associated only with macrophages. Ironically, more recent studies have confirmed that indeed stellate cells can phagocytose apoptotic bodies (85), although the India Ink method used by Kupffer to document phagocytosis almost surely identified macrophages, not stellate cells.

A range of staining techniques were subsequently used to characterize stellate cells, including a Golgi silver method used by Zimmerman to identify “hepatic pericytes,” a fat-staining method used by Ito to define “fat-storing cells” (266), and a silver impregnation technique used by Suzuki to describe “interstitial cells.” More recently, Bronfenmajer, Schaffner, and Popper (75) proposed the name “lipocytes” to reflect their role in fat (vitamin A) uptake and pointed out the resemblance of these cells to fibroblasts. Finally, Nakane (433) and Wake (676–678) firmly established the stellate cell as a discrete cell type capable of storing vitamin A. Wake (676–678), using Kupffer’s original gold chloride method to provide the definitive descriptions of stellate cells in situ, thereby established that “perisinusoidal cells” were the same as those described initially by Kupffer almost 100 years earlier.

An important functional role of stellate cells in liver repair emerged from the seminal descriptions by Kent (295) and others (409, 459, 718) revealing the close proximity of this cell type to collagen fibers in injured liver. Their work also suggested that stellate cells were precursors to the “fibroblasts” often described in liver injury. The consistent morphological association between hepatic stellate cells and extracellular matrix (398) provoked interest in the early 1980s in developing methods to isolate stellate cells from rat (172, 321), mouse (103), and human liver (171, 699) (see sect. IV.A).

B. Nomenclature

With the explosive growth in studies of hepatic stellate cells, confusion arose because of its many different names, prompting investigators in the field to agree in 1996 to a standardized name, hepatic stellate cell, to refer to the resting form of this cell type found in normal liver, a term now widely adopted (448a), instead of a litany of
synonyms, including perisinusoidal cell, Ito cell, lipocyte, parasinusoidal cell, and fat-storing cell.

II. ULTRASTRUCTURE AND MORPHOLOGICAL FEATURES

Hepatic stellate cells are located in the subendothelial space, between the basolateral surface of hepatocytes and the anti-luminal side of sinusoidal endothelial cells. They comprise approximately one-third of the nonparenchymal cell population and ∼15% of the total number of resident cells in normal liver (200, 271). Some studies describe a slight pericentral predominance in normal human liver (75), while in porcine liver they are more prominent in periportal zones (682); the functional significance of these divergent patterns between species, if any, is unclear.

A. Ultrastructure

Stellate cells in normal liver have spindle-shaped cell bodies with oval or elongated nuclei (see Fig. 2). Their perikaryons lie in recesses between neighboring parenchymal cells. Ultrastructurally, their have moderately developed rough endoplasmic reticulum (rER), juxtanuclear small Golgi complex (142), and prominent dendritic cytoplasmic processes (Fig. 3) (674). The subendothelial processes wrap around sinusoids between endothelial cells and hepatocytes. On each of these processes, there are numerous thorny microprojections (spines) (679). The function of these projections had been obscure until a recent, elegant study has demonstrated that these protrusions serve a vital role as the cell’s leading edge in “sensing” chemotactic signals, and then transmitting them to the cell’s mechanical apparatus to generate a contractile force (414).

A single stellate cell usually surrounds more than two nearby sinusoids (679). On the other side of the cell (i.e., the anti-luminal surface), multiple processes extend across the space of Disse to make contact with hepatocytes (679, 680). This intimate contact between stellate cells and their neighboring cell types may facilitate intercellular transport of soluble mediators and cytokines. In addition, stellate cells are directly adjacent to nerve endings (56, 658), which is consistent with reports identifying neurotrophin receptors (95), and with functional studies confirming neurohumoral responsiveness of stellate cells (336, 455, 550).

B. Retinoid Storage

The most characteristic feature of stellate cells in normal liver is their cytoplasmic storage of vitamin (retinoid) droplets (678). In unfixed tissue or cultured cells, the retinoid droplets exhibit a striking, rapidly fading blue-green autofluorescence when excited with the light of ∼328 nm (Fig. 4) (174, 499). The number of droplets varies with the species and the abundance of vitamin A stores of the organism (499, 587). The vitamin A droplets in stellate cells display a heterogeneous pattern, with the volume of droplets differing depending on the intralobular position of the cells (192). Vitamin A fluorescence is more concentrated in periportal regions than pericentral regions (682, 739). Two types of vitamin A droplets have
been described (675): type I droplets are membrane bound and of variable size, but usually smaller than 2 μm in diameter. They are likely derived from “multivesicular bodies,” which are considered a type of lysosome (194, 708). Type II droplets are not membrane bound and are larger (up to 8 μm). The relationship between types I and II droplets and their functional differences are unclear.

According to Wake (675), type II fat droplets form by

**FIG. 3.** Ultrastructure of cultured stellate cells. Primary rat hepatic stellate cells cultured for 7 days on either uncoated plastic (*left panel*) or Matrigel (*right panel*). Cells on plastic become activated and are flat, with well-developed endoplasmic reticulum (ER) and some lipid droplets (L). In contrast, cells on Matrigel (GM, gel matrix) remain quiescent with condensed nuclear chromatin (N) and a high density of vitamin A-containing lipid droplets. Acellular debris (D) and secreted matrix (M) are trapped within the Matrigel surrounding the cell (bar = 10 μm). [From Friedman et al. (173).]

**FIG. 4.** Cultured hepatic stellate cells in primary culture. *A:* high-power phase (*left panel*) and fluorescence (*right panel*) micrograph of primary cultured rat stellate cells, demonstrating cytoplasmic vitamin A droplets that fluorescence when excited by ultraviolet light (bar = 20 μm). *B:* low-power fluorescence micrograph of rat hepatic stellate cells in primary culture on plastic for 1 wk, photographed under ultraviolet light (bar = 80 μm). [From Friedman et al. (174).]
fusion of several type I droplets. Yamamoto and Ogawa (708), however, believed type II droplets to be the precursor of type I droplets.

A well-known feature of artic animals, particularly polar bears, seals, and Arctic foxes, is their high concentration of hepatic vitamin A (586), such that early explorers who ate uncooked polar bear liver suffered from a syndrome of hypervitaminosis A, which is characterized by severe liver injury (449). However, there are no distinct features of these artic mammals identified to date that distinguish their vitamin A storage pathways from those of humans, and thus the reason why these animals are protected from hepatic toxicity due to vitamin A is unclear. Moreover, the requirement for vitamin A-storing cells appears to be a vital evolutionary trait, since stellate cells can be identified even in relatively primitive vertebrates including halibut (722) and the lamprey (681).

During liver injury, the fine structure of stellate cells changes considerably. They lose their characteristic droplets and become “activated” (see sect. vi). The rER becomes enlarged, accompanied with a well-developed Golgi apparatus, suggesting active protein synthesis (174, 421) (Fig. 4). Bundles of numerous microfilaments appear beneath the cell membrane (142). The activated stellate cells then evolve into myofibroblast-like cells (see sect. vi) with newly formed collagen fibrils surrounding them.

III. ORIGIN AND CYTOSKELETAL PHENOTYPE OF STELLATE CELLS

A. Embryologic Origin(s)

The embryologic origin of stellate cells has been elusive. Currently, the bulk of evidence supports their originating from either endoderm (300, 624, 666) or the septum transversum (553) as it forms from cardiac mesenchyme during invagination of the hepatic bud (135, 728, 733). In support of a septum transversum origin, stellate cells express the mesoderm transcriptional factor Foxf1, which is typically localized to the septum transversum mesenchyme during liver development (280). In support of an endoderm origin, on the other hand, it has been suggested that stellate cells and hepatoblasts share a common origin based on the transient coexpression of cytokeratins in both cell types (300, 666).

Stellate cells appear in the second half of the third month of gestation in human development (193). At birth in rats, stellate cells have still not reached their final size, which requires an additional 5 weeks (680). A more recent study has characterized a population of vitamin A-storing cells from day 13 fetal rat liver having a surface phenotype of intercellular adhesion molecule 1 (ICAM-1)+, vascular cell adhesion molecule 1 (VCAM-1)+, and β3-integrin+ (331). The cells are able to proliferate in serum-free hormonally defined medium and express hepatocyte growth factor (HGF), stromal-derived growth factor-1, and Hlx homeodomain transcription factor, implicating them in regulating hepatic development. Further characterization of these cells is likely to lead to efforts to assess their contribution to hepatocellular growth and progenitor cell expansion.

In humans, a population of cells has been characterized in midgestation of embryonic liver development using specific antibodies that are CD34+ cytokeratin (CK)7/8+ and also express CD13, CD59, nerve growth factor receptor (NGFR), desmin, and α-smooth muscle actin (α-SMA), leading the authors to conclude that they represent embryonic precursors of adult stellate cells derived from endoderm (193, 624). These cells were larger with more cytoplasm than CD34+CK7/8− cells and had cytoplasmic projections, also characteristic of stellate cells.

Confusion has increased in the past decade because a neural crest origin has also been suggested based on stellate cells’ expression of several neural crest markers, including glial fibrillary acidic protein (GFAP), nestin, neurotrophins and their receptors, N-CAM, synaptophysin, nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), Rho-N, N-cadherin (192), as well as cellular prion protein (249). However, fate mapping studies of neural crest-derived cells in developing mouse liver have recently failed to localize to hepatic stellate cells during late gestation (94, 193), undermining the possibility of a neural origin.

A separate issue is whether stellate cells and sinusoidal endothelial cells derive from a common precursor cell, a likely possibility given their shared mesenchymal phenotype, close proximity in situ, and joint expression of several angiogenic effectors, for example, receptors for vascular endothelial cell growth factor (VEGF) (10). However, no studies have specifically addressed this issue, either in models of development, liver injury, or regeneration following partial hepatectomy, despite the fact that endothelial cells are vital to liver development (403).

The source of activated stellate cells and myofibroblasts in liver injury has provoked extensive study and debate (590), especially the notion that bone marrow contributes a substantial fraction of these cells. This issue is discussed in detail in section IVB; however, at least one study indicates that bone marrow may also contribute to quiescent stellate cells as well (26), possibly from circulating “fibrocytes” that home to the liver (314). Mice administered a bone marrow transplant containing cells expressing green fluorescent protein (GFP) but without liver injury had evidence of GFP expression in their livers (26). Although the turnover of stellate cells in normal liver is unknown, it seems unlikely that substantial repopulation from bone marrow occurs in the absence of liver injury or a specific stimulus to bone marrow cell recruit-
ment. Moreover, recent studies examining bone marrow contributions to hepatocyte repopulation have emphasized the important contribution of cell fusion to the apparent amplification of bone marrow-derived cells (216, 651).

B. Heterogeneity and Plasticity of Hepatic Stellate Cells

As implied in the preceding paragraphs, the development of antibodies to a range of cytoskeletal and cell surface markers has facilitated the extensive characterization of the stellate cell’s phenotype. What has emerged from these analyses is an appreciation of their tremendous heterogeneity and plasticity in adult liver, depending on their lobular location, the species examined, and whether the tissue is normal or injured.

In 1984, Yokoi (718) detected desmin in stellate cells, an intermediate filament typical of contractile cells. This finding suggested a similarity between stellate cells and myogenic cells. Since then, desmin has been widely used as a “gold standard” for identifying stellate cells in rodent liver, although in humans its expression is unreliable (171, 571). A more recent study suggests that a significant fraction of stellate cells may lack vitamin A (31, 517), indicating a heterogeneous phenotype in these cells, as detailed below. Desmin-negative cells are concentrated in the pericentral zone, where they may represent up to 50% of the total stellate cell pool whereas perportal stellate cells are typically desmin positive (31).

α-SMA is one of the six actin isoforms expressed in mammalian tissues. Its presence is typical for vascular smooth muscle cells (179, 606) and myofibroblasts, or contractile fibroblasts, where it is localized within microfilament bundles (572, 589). Induction of α-SMA is the single most reliable marker of stellate cell activation (see sect. vi), because it is absent from other resident liver cells in either normal or injured liver except the smooth muscle cells surrounding large vessels. Interestingly, while its expression connotes a contractile phenotype, its genetic deletion leads to enhanced fibrosis in a rodent model of renal injury (632). These early observations of stellate cell plasticity rapidly led to the conclusion that rather than a single cell type with an identical retinoid and cytoskeletal phenotype, stellate cells contain variable amounts of vitamin A and differing combinations of intracellular filaments, depending on their lobular location, the species studied, whether the liver was normal or injured, and the nature of the liver injury (i.e., biliary vs. parenchymal). Moreover, as described in section viA, there is a continuum of changes in gene expression during stellate cell activation, such that the quiescent cell first becomes activated, then continues to evolve into a myofibroblast-like cell. However, activated stellate cells are distinct from myofibroblasts in their vitamin content, contractile activity, and relative responsiveness to cytokines, particularly transforming growth factor (TGF)-β. Even when stellate cells reach replicative senescence, the pattern of gene expression continues to evolve, with acquisition of a more inflammatory and less fibrogenic phenotype (574).

The plasticity of stellate cell phenotype was underscored by findings from a double transgenic mouse in which a GFP was driven by the collagen I promoter, while a red fluorescent protein (RFP) was controlled by the α-SMA promoter (166, 367). In this study there were mixed populations of activated cells, some of which expressed GFP or RFP alone, others of which expressed both. Specific patterns of gene expression were seen in cells expressing α-SMA, with higher levels of ICAM-1, MMP-13, reelin, TIMP1, and synaptophysin mRNAs. Along this theme, another study demonstrated that stellate cell activation in liver fibrosis is also associated with a switch from E- to N-cadherin expression (353), raising the interesting prospect that stellate cells undergo epithelial to mesenchymal transition (601). In addition, in cholestatic liver injury, portal fibroblasts may be a more important source of activated myofibroblasts than stellate cells around proliferating bile ducts (41). Collectively, these findings reinforce earlier histochemical data highlighting the heterogeneity of stellate cells with respect to both classical markers of stellate cell activation and even raise the possibility of transdifferentiation from epithelium.

C. Extrahepatic Stellate Cells

Following the detailed characterization of hepatic stellate cells, it became clear that similar cells existed in other organs. In particular, pancreatic stellate cells are nearly identical to hepatic stellate cells, and both are presumed to share a common origin (77, 466). Pancreatic stellate cells display the same heterogeneous cytoskeletal phenotype as hepatic stellate cells. The similarity is further reinforced by a direct transcriptome analysis of the two cell types, revealing that while isolated human hepatic and pancreatic stellate cells differ considerably compared with skin fibroblasts, there were only 20 mRNAs that were different between the two types of stellate cells. Most of the divergent genes were mRNAs regulating extracellular matrix expression and turnover, cell adhesion, or cell-cell communication, in addition to three transcription factor genes (77). Furthermore, it is likely that these minor differences between hepatic and pancreatic stellate cells could have arisen primarily as a result of different culture conditions rather than fundamental differences between the two cell types. Similarities between hepatic and pancreatic stellate cells also extend to pathways of fibrogenesis, including similar roles of cytokines (13) and...
alcohol metabolites (14), especially acetaldehyde (see Ref. 466 for review).

Still, there are fundamental differences in the microenvironments of hepatic and pancreatic stellate cells that could condition these cells to respond differently to normal homeostatic controls and to injury. For example, liver receives a dual blood supply that includes predominantly venous blood, such that hepatic stellate cells are less prone to ischemia when arterial blood flow is compromised. On the other hand, pancreatic injury, unlike hepatic injury, is associated with disruption of zymogen granules containing proteases, exposing resident cells to proteolysis. It is tempting to speculate that either or both of these differences may contribute to the enhanced regenerative capacity of liver compared with pancreas. Another difference is that desmoplasia is a far more common component of pancreatic cancer than hepatocellular carcinoma, with evidence that pancreatic cancer cells release potent fibrogenic mediators (30).

While less thoroughly characterized, vitamin A-storing cells are present in a variety of other tissues including lung, kidney, and intestine (243, 431, 678); lipid droplets in these sites increase in rats with hypervitaminosis A (431). In addition, cell types resembling activated stellate cells are also demonstrable in injured kidney (361) and lung (294), where pathways of fibrogenesis are thought to be quite similar. One key difference between kidney and liver fibrogenic cells, however, is the apparently larger contribution of epithelial to mesenchymal cell transition in renal fibrosis than in liver (281, 601).

IV. MODELS AND METHODS OF CHARACTERIZING STELLATE CELLS

A. Cell Isolation Methods

The development of techniques for isolating and cultivating hepatic stellate cells represented a major advance in exploring the cell’s roles in normal and injured liver. Studies 25–30 years ago characterized the growth of mesenchymal cells derived from liver tissue, which in retrospect may have been derived from stellate cells (182, 672). Cell studies of this type described a “fibroblast-like” phenotype with potential for extracellular matrix production. With the realization that such cells were likely derived from stellate cells, Knook et al. (321), then our laboratory (172, 174), utilized in situ digestion followed by density gradient centrifugation to isolate stellate cells based on their buoyancy attributable to intracellular vitamin A. Initially these methods required vitamin A supplementation to increase yields, until it was recognized that vitamin A content increased in normal rats with age. By using larger, older rats (>350 g), yields of 40–100 million cells per normal animal (95–99% purity) were obtained routinely, which were increased further in animals with liver injury (unpublished observation). Several different gradient materials can be utilized, including metrizamide (321), arabinogalactan (172), or Nycodenz (241). Considerations for the choice of material include precision, reproducibility, cost, and ease of preparation. Gradient separation has also been used to successfully isolate stellate cells from normal human liver suitable for primary culture, although purity is less than for rodent cells (171).

Density gradient separation remains the most widely used approach for stellate cell isolation, but favors the isolation of cells that are relatively vitamin A-rich and therefore less “activated.” Indeed, in animals with liver injury, large numbers of stellate cells are recovered from higher density (i.e., lower level) gradient layers; such vitamin A-poor cells are typically more activated in terms of cytoskeletal markers and extracellular matrix gene expression. The difficulty with these vitamin A-poor isolates is their heterogeneity, since they may contain significant numbers of sinusoidal endothelial cells and Kupffer cells (172). Studies of such isolates therefore may be confounded because of paracrine stimulation of stellate cells by soluble mediators from other nonparenchymal cells, an issue discussed in section cVH describing gene array profiling of stellate cells.

Two cell isolation approaches that avoid density gradients are fluorescent cell sorting and explant culture. Cell sorting, based on endogenous vitamin A fluorescence, has been reported in one study (406). Lower yields and dependence on costly technology greatly limit its applicability, although it remains valuable for obtaining ultrapurified stellate cells. Outgrowth of activated stellate cells from human liver biopsy material has gained favor (60, 691) and is reminiscent of earlier studies (182, 672), albeit now utilizing more refined cell markers. The limitations of this approach are the potential heterogeneity of the culture and the inability to track early events in cellular activation, since the method relies on outgrowth of activated cells on plastic in tissue culture. Still, careful characterization of the cells by immunostaining for cytoskeletal markers and extracellular matrix products does allow for the generation of meaningful data.

While methods for stellate cell isolation were initially developed in rats and then adapted to humans, the development of transgenic and knockout mouse models has more recently required the isolation of murine stellate cells. The methods required are fundamentally the same but require a larger number of animals to achieve an adequate yield. A growing number of such models have utilized either standard isolation or in situ analysis with cell specific markers to characterize the cells (239, 280, 510, 608, 645).
B. Cell Lines

To overcome the need for primary cell isolation entirely, stellate cell clones/lines have been developed which recapitulate some features of the in vivo activated phenotype; their use has increased dramatically in recent years (219). Such stable, immortal cell lines offer the advantage of a ready supply of cells, homogeneity, and the potential for many investigators to work in the same carefully defined system. Cell lines currently in use have been generated by either spontaneous immortalization in long-term culture, stable expression of simian virus 40 (SV40) T antigen, or ectopic expression of telomerase. Cell lines each differ somewhat in their state of activation, transfectability, and mRNA expression profiles (see sect. V). Cell lines currently in use have been generated by either spontaneous immortalization in long-term culture, stable expression of simian virus 40 (SV40) T antigen, or ectopic expression of telomerase. Cell lines each differ somewhat in their state of activation, transfectability, and mRNA expression profiles (see sect. V), but in general have accelerated progress in elucidating stellate cell biology and hepatic fibrosis. However, it is prudent to always validate findings derived from cell lines to the in vivo state using either primary stellate cells or in situ methods to confirm that gene or protein expression identified in cell lines is physiologically relevant. A large number of lines have been reported, but only those most extensively studied are described below.

Several rodent stellate cell lines have been characterized. Greenwel, Rokkind, and co-workers (208) reported stellate cell clones derived from normal or CCl4-treated rat liver, which have variable levels of collagen gene expression and responsiveness to interleukin-6. Subsequently, our laboratory characterized a rat stellate cell line generated by stable expression of the SV40 T antigen (671). This line, termed “HSC-T6,” is particularly valuable for studies of retinoid metabolism based on their similar retinoid phenotype as primary cells (671). Similarly, the “PAV-1” line displays features of retinoid metabolism akin to that of primary cells (563, 564). A recent addition is the rat line “PQ” generated by single cell cloning, which has key features of primary stellate cells (474), although there is not evidence yet that the line is truly immortalized.

Several human stellate cell lines have also been generated. The L190 line is derived from a human hepatic mesenchymal cell tumor (428). The cells accumulate collagen matrix, stellate cells are more fibrogenic in response to cytokines, hypoxia, and other stimuli (34, 85–87, 89, 228, 483, 596, 629, 636, 730). Other human cell lines include one created by telomerase expression in the L190 cells (597) and another derived from explant culture (691).

A recent report describes a cryopreservation technique for freezing primary stellate cells using dimethyl sulfoxide (442). If reproducible in other laboratories, the technique will also accelerate progress by enabling the sharing of cells between investigators, especially those without the means to isolate their own primary cells.

C. Effects of Matrix and Culture Conditions

Progressive cellular activation, as defined by loss of vitamin A, proliferation, and increased extracellular matrix production, occurs when stellate cells are plated in primary culture on standard tissue culture plastic (see Fig. 3) (29, 173, 195). This “spontaneous activation” can be exploited to study cellular events similar to those occurring in liver injury and can be further accelerated by incubation in conditioned medium from hepatic macrophages (168, 404, 405). Early primary culture is important for studying signaling events in stellate cell activation, but is limited by the heavy dependence on repeated cell isolations and by prep-to-prep variability. The problem can be overcome somewhat by passaging cells with trypsin and replating to increase yields; however, this leads to progressive deviation from the quiescent phenotype.

In addition to using uncoated plastic as a culture substratum, stellate cells grow well on a variety of extracellular matrices which can up- or downregulate their activation (579). For example, when grown on a type I collagen matrix, stellate cells are more fibrogenic in response to TGF-β than on type IV collagen (114). Even more striking is the preservation of a quiescent phenotype when stellate cells are maintained on a laminin-rich gel that mimics the effects of a basement membrane (173, 181, 463). This quiescent phenotype can also be main-
tained if cells are prevented from adhering by growth in suspension on a nonadherent surface (176).

While the effect of a gel on preserving stellate cell quiescence was reproducible, we and other investigators were unable to define a specific matrix constituent that conferred quiescence. However, a fascinating explanation for the effects of a gel substratum has been offered by recent studies implicating matrix stiffness as the key determinant of stellate cell activation in these systems (694). Thus the deformability of the substrate, in addition to, or instead of, its chemical composition may regulate stellate cell responsiveness. While the receptors that mediate these responses are not firmly identified, integrins are strong candidates based on their important role in mediating cell-substratum interactions in stellate cells and other mesenchymal cell types. The emergence of matrix stiffness as regulator of stellate cell biology resonates with recent clinical studies utilizing a device that measures stiffness to determine the physical state of liver and in particular its matrix content (160). Continued efforts to refine both chemical and physical determinants of stellate cell function are critical to optimize methods for developing artificial liver devices, where the physical properties of the substratum and cell-cell interactions may be vital to preserving differentiated hepatic function (215). In particular, use of three-dimensional culture systems may be particularly relevant to such efforts by recapitulating a more physiological microenvironment (227, 585, 631).

D. Other Models: Liver Slices, In Vivo Methods

Liver slices were developed decades ago in an attempt to preserve the native milieu of resident liver cells, but were abandoned when methods for primary cell isolation were developed. With continued refinements, however, liver slices again offer some unique advantages (664, 665) and have more recently been used to test drug targeting methods (410, 411), antifibrotic therapies (224), and cell fate during injury and repair following exposure to hepatotoxins (221). The slice technology can be complemented with either real-time PCR for stellate cell-specific genes (665) or laser-capture microdissection to enrich for stellate cells recovered from within the slice.

In vivo methods for stellate cell analysis were developed as a result of refined culture methods and improved antibodies suitable for in situ immunohistochemistry. Maher et al. (371) pioneered the use of stellate cell isolation from injured rodents to characterize their gene expression as a reflection of their in vivo behavior, an approach which has now been adapted to a variety of models and species. Concordance between levels of gene and protein expression in these isolated cells and tissue is extremely high, further validating the method. At the same time, countless studies have used tissue immuno-
expression in both stellate cells and the epithelial component of the ductular reaction to various liver diseases and cholangiocarcinoma (569). Similarly, in a rat study of hepatic responses to a carcinogen, a subset of nestin positive cells (i.e., stellate cells) coexpressed hepatocyte and epithelial markers (323). Finally, the recent characterization of a fetal hepatic stellate cell isolate from rat (331) could accelerate efforts to explore the stellate cell’s role in bile duct and progenitor expansion in culture and in vivo models.

In addition to their emerging role in hepatic development, there is growing evidence that stellate cells are also vital to the hepatic regenerative response in adult liver, but further investigation is urgently needed. An important study has identified neurotrophin signaling as a paracrine pathway in stellate cells that contributes to hepatocellular growth following injury, in part through stimulation of HGF secretion by stellate cells (481). In a similar approach, mice heterozygous for the Foxf1 forhead transcription factor (Foxf1+/−) display defective stellate cell activation after CCl4 administration, as assessed by α-SMA expression (280). At the same time, these animals have increased liver cell injury and apoptosis, but reduced fibrosis and diminished expression of Notch-2 and IP-10, compared with wild-type controls. Most intriguingly, the animals have defective epithelial regeneration, although it is difficult to tease out the potential mechanisms based on these data alone. In particular, it is unclear if products of activated stellate cells are required to attenuate hepatocyte injury, enhance hepatocellular regeneration, or both. The role of stellate cells in hepatic regeneration would be ideally addressed if methods are developed to determine the impact of ablating or inactivating these cells on regeneration of normal liver following partial hepatectomy. A genetic model of cell-specific deletion has been quite informative in understanding the role of hepatic macrophages (133, 164) in liver injury and repair, for example.

A number of potential hepatocyte mitogens are secreted by stellate cells, including HGF (368, 568), epidermal growth factor (29, 416, 427), epimorphin (723), and pleiotrophin (20). As yet, however, their relative contribution and modes of regulation during hepatic regeneration have not been clarified.

Even more interesting, a subset of hepatic stellate cells express CD133, which is a stem cell marker (326), suggesting that stellate cells might have pleuripotent potential in developing or adult liver. This very intriguing finding merits further exploration, as two recent studies have identified CD133 as a marker of stemlike cells in several tissues (532, 726), including colon cancer (451, 526).

### B. Retinoid Metabolism

In normal liver, stellate cells play a key role in the storage and transport of retinoids (vitamin A compounds). Under physiological conditions, ~50–80% of total retinoid of the body is stored in the liver (62), of which 80–90% is stored in stellate cells (240, 241). Most vitamin A is stored in cytoplasmic droplets in the form of retinyl esters, predominantly retinyl palmitate (240, 241). The composition of these droplets is affected by dietary intake. They contain not only retinoids, but also significant amounts of triglycerides, phospholipids, cholesterol, and free fatty acids (425, 706).

Dietary retinol in the intestinal epithelium is esterified with long-chain fatty acids and packaged into chylomicrons for transport to the systemic circulation through mesenteric lymphatics. In the liver, these retinol-containing chylomicrons are taken up by hepatocytes and then transferred to stellate cells for storage; a small amount remains within hepatocytes. Within hepatocytes, retinyl esters are hydrolyzed to free retinol before being transferred to stellate cells (63). This process is mediated by retinol-binding protein (RBP) (61). In addition, stellate cells also take up RBP-bound retinoids directly from circulating blood (8). Direct release of RBP-bound retinol from stellate cells into plasma may also occur (62). The storage and transport of retinoids are influenced by the vitamin A status of the animal. In vitamin A-deficient conditions, dietary retinoids transported to the liver are rapidly bound to RBP in hepatocytes and exported to the circulation without transfer to stellate cells (40, 63).

Several retinoid-related proteins have been identified in stellate cells, including cellular retinol-binding protein (CRBP), retinol palmitate hydrolase, cellular retinoic acid-binding protein (CRABP), bile salt-dependent and -independent retinol ester hydrolase, and acyl coenzyme A:retinal acyltransferase (59, 175). Whether stellate cells produce RBP is still in question, because of contradictory reports on the presence of RBP mRNA in stellate cells between different studies (64, 175).

#### I. Effects of retinoids on stellate cells

The biological role of retinoids in regulating stellate cell activation remains a puzzle. Although loss of retinoid is a prominent feature accompanying stellate cell activation both in vivo (421) and in culture (175), it is unknown whether this process is a prerequisite for activation to occur. The reports about effects of retinoids on stellate cells and fibrogenesis are contradictory (115, 116, 199, 236, 423, 460, 461, 563, 582, 583, 588). In culture, both retinol and retinoic acid suppress stellate cell proliferation, and retinoic acid (RA) is 1,000 times more potent than retinol (116). In contrast, 9-cis-RA and 9,13-di-cis-RA, two metabolites of RA, promote fibrosis by upregu-
lating plasminogen activator, which in turn induces the production and activation of TGF-β (460, 461). This process is mediated by RA receptor (RAR)-α. However, in another study using a rat model of fibrosis induced by bile duct ligation, the increase in TGF-β production was attributed to diminished RA signaling in stellate cells (457). More recently, divergent effects of all-trans-RA and 9-cis-RA on stellate cells have been observed (234). There are also different effects between natural and synthetic retinoids (236).

Since almost all the vitamin A in liver is stored in stellate cells, studies examining retinoid content in whole liver predominantly reflect the features of retinoids in stellate cells. Accordingly, loss of total retinoid but increased RA in liver during injury may have implications for stellate cell function (440). These observations differ from changes observed in vitamin-A deficient animals, in whom expression of lecithin:acyl transferase (LRAT), the enzyme responsible for esterifying retinol, is downregulated rapidly along with a retinoic acid responsive cytochrome P-450, Cyp26 (551).

C. Immunoregulation

The emergence of stellate cells as significant mediators of hepatic immunoregulation has been among the most surprising discoveries about the cell type (369) (see Fig. 5). Stellate cells can amplify the inflammatory response by inducing infiltration of mono- and polymorphonuclear leukocytes. Activated stellate cells produce chemokines that include monocyte chemotactic peptide (MCP)-1 (393), CCL21 (66), RANTES, and CCR5 (580). They express toll-like receptors (TLRs) (472), indicating a capacity to interact with bacterial lipopolysaccharide (LPS), which in turn stimulates stellate cells (76). Stellate cells also can function as professional antigen presenting cells (660, 670, 700) that can stimulate lymphocyte proliferation or apoptosis (322). In addition to mononuclear cell chemoattractants, stellate cells produce neutrophil chemoattractants, which could contribute to the neutrophil accumulation characteristic of alcoholic liver disease (372), as well as complement protein C4 (153), which contributes to the liver’s inflammatory response.

Stellate cells both regulate leukocyte behavior and are affected by specific lymphocyte populations. For example, CD8 cells harbor more fibrogenic activity towards stellate cells than CD4 cells (559), which may explain in part the increased hepatic fibrosis seen in patients with hepatitis C virus (HCV)/human immunodeficiency virus (HIV) coinfection, where CD4/CD8 ratios are reduced, compared with patients mono-infected with HCV alone.

The role of pattern recognition receptors in stellate cells is also being uncovered. Activated human stellate cells express TLR4 and the other two molecules (CD14 and MD2) which together form the LPS receptor complex (472). Low concentrations of LPS induce activation of NFκB and JNK in activated human stellate cells, leading to expression of chemokines and adhesion molecules. Mouse stellate cells express TLR4 and TLR2 and respond to a range of pathogen-associated molecular patterns (PAMPs) including LPS, lipoteichoic acid, and N-acetyl muramyl peptide with secretion of interleukin (IL)-6.
TGF-β, and MCP-1 (76, 471). These in vitro results suggest that bacterial wall products produce an inflammatory phenotype in stellate cells, but notably do not induce matrix deposition, since fibronectin and collagen transcripts were not increased. Signaling to stellate cells via TLR4 may function to enhance an adaptive immune response against bacterial pathogens. It is also possible that ligation of TLR4 is just the initial step of a series of signals that are required for differentiation of stellate cells into a fully fibrogenic phenotype. This may occur by recruitment of Th2-type Kupffer cells or other immune cells, which provide additional signals such as IL-13. In addition, TLR4 signaling leads to downregulation of a TGF-β pseudoreceptor, BAMBI (584), which thereby amplifies fibrogenic activity of stellate cells.

Although TLRs and members of the caterpillar family were identified as recognizing molecular patterns in pathogens, there is no theoretical constraint limiting recognition of “self” molecular patterns that are usually hidden inside cells. In fact, there is increasing evidence that self molecules may activate some of these receptors. The best evidence is presentation of apoptotic mammalian DNA, which is relatively CpG rich and can activate TLR9 (669). This pathway is important in auto-activation of B cells and may have a role in the activation of stellate cells by apoptotic cells (83). A further example is the activation of immune cells by uric acid, which is dependent on the presence of NALP3 and the adaptor molecule ASC (399). It will be important to identify the molecules from apoptotic bodies that provoke stellate cells, as none have been identified; pattern recognition receptors may play an important role in this process. Of equal importance, the identification of apoptotic fragments from damaged hepatocytes as fibrogenic stimuli is an important conceptual advance, which has led to new approaches to hepatoprotective therapies using caspase inhibitors in patients with chronic liver disease (663).

The interactions between the immune system and stellate cells are not unidirectional; instead, there is significant evidence that stellate cells also modulate the hepatic immune response. This is best demonstrated by their expression of the costimulatory molecule B7-H1 (PDL-1 or programmed death ligand-1) on activated but not resting stellate cells (725). B7-H1 binds to PD1, which is an immunoglobulin superfamily member related to CD28 and CTLA-4, but which lacks the membrane proximal cysteine that allows these molecules to homodimerize (206). PD1 is expressed on a range of immune cells including CD4+ T cells, and at very low levels PD1 activation is sufficient to inhibit the earliest stages of T-cell activation. PD1 also inhibits expression of the cell survival gene bcl-xl and limits activation of Akt. The final effect of PD1 may be very context dependent, and influenced by the stage of T-cell differentiation and the degree of stimulation via the T-cell receptor. Stellate cells induced apoptosis of T cells activated in an alloassay, but did not inhibit proliferation or cytokine production. This suggests that activated stellate cells have a mechanism for inhibiting T cell-mediated cytoxicity and conversely can induce T-cell apoptosis. An immunotolerizing role is also suggested by experimental models in mice in which transplanted stellate cells protect islet allografts from rejection (102), as well as enhancing engraftment of transplanted hepatocytes (49).

D. Secretion of Lipoproteins, Growth Factors, and Cytokines

1. Apolipoproteins and lipids

Stellate cells secrete apolipoprotein E (162, 512), a feature characteristic of smooth muscle cells (375). In one study they also expressed apo A-I and apo A-IV (512), whereas in another, the mRNAs for apo A-I and A-IV were not detected by PCR (162). The functional importance of apolipoprotein production in stellate cells is not clearly defined.

Another family of lipids, prostaglandins, is also secreted by stellate cells. Prostaglandins play important roles in hepatic metabolism and inflammation, as well as neural-mediated vasoregulation. In early primary culture, rat stellate cells rapidly release prostaglandin (PG) F2α and D2 when incubated with the neurotransmitter norepinephrine or ATP (25). This finding has special in vivo relevance because of the close proximity of stellate cells to nerve endings in normal liver (see sect. ii). Highly activated rat stellate cells also produce PGI2 and PGE2 in response to ethanol, which appears to be dependent on production of acetaldehyde (159). The production of leukotriene C4 and B4 has also been reported (48). To date, the roles of prostaglandins in stellate cell activity are not fully clarified.

2. Production of growth factors and cytokines

Stellate cells are an important source of cytokines in the liver (see Table 1). Signal transduction through binding of these cytokines to their membrane receptors comprises the main pattern of cell-cell interactions in both normal and injured liver. A consistent theme throughout studies of stellate cell signaling is the importance of autocrine signaling. For virtually all growth factors, stellate cells not only secrete cytokines but also respond to them, emphasizing the importance of tightly regulated local control of cytokine action within the pericellular milieu.

Stellate cells secrete TGF-α and epidermal growth factor (EGF), two potent epithelial growth factors that play important roles in hepatocyte proliferation during liver regeneration (29, 416, 427). TGF-α and EGF also stimulate mitosis in stellate cells (416, 699), creating an
TABLE 1.  Repertoire of cytokines and membrane receptors associated with hepatic stellate cells

<table>
<thead>
<tr>
<th>Cytokine Family</th>
<th>Cytokines</th>
<th>Receptor(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Proliferative or fibrogenic</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transforming growth factors</td>
<td>TGF-β1/TGF-α, BMP4 and BMP6</td>
<td>TGF-β receptor types I, II and III; mannose-6-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>phosphate receptor</td>
</tr>
<tr>
<td>Platelet-derived growth factors</td>
<td>PDGF-B</td>
<td>β-PDGFB and α-PDGF-R</td>
</tr>
<tr>
<td>Epidermal growth factor</td>
<td>Stem cell factor</td>
<td>EGF receptor</td>
</tr>
<tr>
<td>Stem cell factor</td>
<td></td>
<td>c-met</td>
</tr>
<tr>
<td>Hepatocyte growth factor</td>
<td>HGF</td>
<td>α/β3-integrin, low-density lipoprotein receptor-related</td>
</tr>
<tr>
<td>Connective tissue growth factor</td>
<td>CTGF (CCN2)</td>
<td>protein (LRP)</td>
</tr>
<tr>
<td>(CCN2)</td>
<td></td>
<td>FGF receptor-2 (fg)</td>
</tr>
<tr>
<td>Fibroblast growth factors</td>
<td>aFGF and bFGF</td>
<td>ET-A and ET-B receptors</td>
</tr>
<tr>
<td>Endothelin-1</td>
<td>ET-1, ECE</td>
<td>OB-Ra and OB-Rb</td>
</tr>
<tr>
<td>Leptin</td>
<td>Leptin</td>
<td>uPAR</td>
</tr>
<tr>
<td>Plasminogen</td>
<td>UPA/PAI-1</td>
<td>VEGFR-1 (Flh1) and VEGFR-2 (Flk1)</td>
</tr>
<tr>
<td>Vascular endothelial cell growth</td>
<td>VEGF</td>
<td>IGF-IR</td>
</tr>
<tr>
<td>factor</td>
<td>IGF-I and IGF-II</td>
<td>Thrombin receptor</td>
</tr>
<tr>
<td>Thrombin</td>
<td>NR</td>
<td>Integrins α1β1, α2β1, α6β4, α5β1, α8β1, αVβ1, αVβ3,</td>
</tr>
<tr>
<td>RGD containing and integrin</td>
<td>Fibronectin, tenascin</td>
<td>integrin-linked kinase</td>
</tr>
<tr>
<td>ligands</td>
<td></td>
<td>Discoidin domain receptors 1 and 2</td>
</tr>
<tr>
<td>Fibrillar collagens</td>
<td>Collagens I, II</td>
<td>CB1 receptor</td>
</tr>
<tr>
<td>Cannabinoids</td>
<td>NR</td>
<td>P2Y receptors</td>
</tr>
<tr>
<td>Purines</td>
<td>Ubiquitous</td>
<td>A(2a) adenosine receptor</td>
</tr>
<tr>
<td>Adenosine</td>
<td>Ubiquitous</td>
<td>Angiotoxin II types 1 and 2 receptors</td>
</tr>
<tr>
<td>Renin-angiotensin</td>
<td>Angiotoxin II, renin, ACE</td>
<td>SRR2, SRR3, and SRR5 receptors</td>
</tr>
<tr>
<td>Serotonin</td>
<td>NR</td>
<td>Patched</td>
</tr>
<tr>
<td>Hedgehog</td>
<td>Native hedgehog and sonic hedgehog</td>
<td>NR</td>
</tr>
<tr>
<td>Galectin</td>
<td>Galectin-3</td>
<td></td>
</tr>
<tr>
<td>Advanced glycation end products</td>
<td>NR</td>
<td>Receptors for AGE (RAGE)</td>
</tr>
<tr>
<td>(AGE)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Macrophage colony stimulating</td>
<td>M-CSF</td>
<td></td>
</tr>
<tr>
<td>factor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endothelin</td>
<td>ET-1, ECE</td>
<td>ET-A and ET-B receptor</td>
</tr>
<tr>
<td>Platelet activating factor</td>
<td>PAF</td>
<td>PAF receptor</td>
</tr>
<tr>
<td>CD40</td>
<td>CD40 ligand</td>
<td></td>
</tr>
<tr>
<td>Tumor necrosis factor-α</td>
<td>TNF-α</td>
<td>TNFR1, p75NTR</td>
</tr>
<tr>
<td>Chemokines</td>
<td>CXCL1, MCP-1 RANTES, MIP-1, IL-8</td>
<td>CXCR3</td>
</tr>
<tr>
<td>Opioids</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Oxidized LDL</td>
<td>NR</td>
<td>Delta 1 and Delta 2 opioid receptors</td>
</tr>
<tr>
<td>Toll like receptor ligands</td>
<td>NR</td>
<td>CD36</td>
</tr>
<tr>
<td>Interleukin-6</td>
<td>IL-6</td>
<td>TLR4, CD4</td>
</tr>
<tr>
<td>Neurotrophins</td>
<td>NGF, BDNF, NT-4, NT-4/5</td>
<td></td>
</tr>
<tr>
<td>Hepatocyte growth factor</td>
<td>HGF</td>
<td></td>
</tr>
<tr>
<td>Interleukin-10</td>
<td>IL-10</td>
<td></td>
</tr>
<tr>
<td>Cannabinoids</td>
<td>NR</td>
<td>IL-10 receptor</td>
</tr>
<tr>
<td>Adiponectin</td>
<td>Adiponectin</td>
<td>CB2 receptor</td>
</tr>
<tr>
<td>Hepatocyte growth factor</td>
<td>HGF</td>
<td>c-met</td>
</tr>
<tr>
<td>Follistatin</td>
<td>Follistatin</td>
<td></td>
</tr>
<tr>
<td>Fas signaling</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Miscellaneous</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cystatin</td>
<td>Cystatin</td>
<td></td>
</tr>
<tr>
<td>Catecholamines</td>
<td>Norepinephrine</td>
<td>α1A- and β-adrenergic receptors</td>
</tr>
<tr>
<td>5-Hydroxytryptamine</td>
<td>NR</td>
<td>5-Hydroxytryptamine receptor subtypes 1A, 2A, and 2B</td>
</tr>
<tr>
<td>Adrenomedullin</td>
<td>Adrenomedullin</td>
<td></td>
</tr>
<tr>
<td>Complement cascade</td>
<td>NR</td>
<td>C5a receptor</td>
</tr>
<tr>
<td>Natriuretic peptides</td>
<td>NR</td>
<td>Natriuretic peptide receptor B</td>
</tr>
</tbody>
</table>

Shown is a compilation of data reported from all mammalian species describing expression of either miRNA or protein for a broad range of cytokines and soluble factors, and/or their cognate receptors associated with hepatic stellate cells. The table is organized according to their main activity reported, although most of these molecules have many activities. The table does not distinguish whether these molecules are associated with quiescent or activated stellate cells. See text for details. NR, not reported.
autocrine loop for cellular activation. HGF is a more potent hepatocyte mitogen produced by stellate cells (368, 568). Production of HGF by stellate cells diminishes during acute liver injury (368). Stem cell factor (SCF) has also been identified in stellate cells in rats undergoing liver regeneration induced by partial hepatectomy combined with 2-acetoaminofluorene (177). In addition, insulin-like growth factor (IGF) I and II are secreted by stellate cells (487, 737).

Platelet-derived growth factor (PDGF), a dimer of two subunits referred to as A- and B-chain, is the most potent stellate cell mitogen described thus far (488, 491–493). PDGF A-chain mRNA has been detected in activated human stellate cells (387). During liver injury, stellate cells display increased PDGF production as well as the upregulation of PDGF receptors (496, 702). An interesting model emphasizing the activity of PDGF in liver is one in which a mouse with transgenic expression of PDGF-C not only stimulates fibrosis, but also leads to the development of hepatocellular carcinoma (HCC) (113). This is one of only very few models resembling human liver disease in which fibrosis precedes cancer, similar to most cases of HCC, which arise in cirrhotic livers.

Acidic fibroblast growth factor (aFGF) is another mitogenic cytokine that has been identified in stellate cells in situ in late hepatic development and during hepatic regeneration (397). Stellate cells also display an autocrine loop for basic FGF (bFGF), which is mitogenic towards culture-activated rodent and human stellate cells (397, 493, 547, 548, 699).

Stellate cells produce macrophage colony-stimulating factor (M-CSF) (488) and MCP-1 (112, 395), which regulate macrophage accumulation and growth (see sect. vC). MCP-1 production is stimulated by thrombin, IL-1α, interferon-γ, and tissue necrosis factor (TNF)-α (391, 395). It is blocked by H-7, an inhibitor of protein kinase C (PKC) (395), suggesting the involvement of PKC in the signaling pathway leading to MCP production. M-CSF synthesis is stimulated by PDGF and bFGF (488). The secretion by stellate cells of these macrophage growth factors may play a role in amplifying the inflammatory and fibrogenic response during liver injury.

The neutrophil inflammatory response in injured liver is also amplified by stellate cells through the production of platelet activating factor (PAF). PAF promotes chemotaxis of neutrophils and stimulates their activation (489). Its production is increased by thrombin, LPS, and calcium ionophores (489). PAF and its receptors are induced on stellate cells during experimental fibrosis (712).

Generation of an increasing number of chemokines has been ascribed to stellate cells. These include cytokine-induced neutrophil chemoattractant (CINC), a rat form of human IL-8 (372), RANTES (580), C-X-C chemokine ligand 1 (81), and macrophage inflammatory protein-2 (81, 612) among others (385) (see Fig. 5). Upregulation of at least one chemokine, eotaxin, may portend a more aggressive course of hepatitis and fibrosis in patients with chronic HCV (627).

Stellate cells may participate in amplifying the acute phase response by secreting IL-6 (208, 646). LPS, IL-1β, and TNF-α are potent stimuli of IL-6 production (646). On the other hand, IL-10 is an anti-inflammatory cytokine produced by stellate cells.

Upregulation of IL-10 occurs in early stellate cell activation (645, 685) and has prominent antifibrogenic activity by downregulating collagen I expression while upregulating interstitial collagenase. IL-10 knockout mice develop severe hepatic fibrosis following CCl4 administration (364, 365, 644).

Stellate cells also express several adhesion molecules, including ICAM-1 (237), VCAM-1 (318), and neural cell adhesion molecule (NCAM) (317, 435, 436). The expression of ICAM-1 is increased following stellate cell activation and may play a role in lymphocyte adherence to activated stellate cells (237). In situ studies have demonstrated an upregulation of both ICAM-1 and VCAM-1 following CCl4-induced liver injury (318). The peaks of the immunoreactivity of these two molecules coincided with maximal cell infiltration; moreover, the inflammatory cytokine TNF-α increases the transcripts of both CAMs (318). It is likely that ICAM and VCAM are involved in modulating the recruitment of inflammatory cells during liver injury. Stellate cells expressing NCAM have been found in close proximity to nerve endings in the liver (317). The function of this adhesion molecule in stellate cells is not known.

TGF-β is one of the most important cytokines expressed following liver injury. Stellate cells secrete latent TGF-β1 in response to injury, which, after its activation, exerts potent fibrogenic effects in both autocrine and paracrine patterns, with autocrine being most important (58, 209, 213, 359, 504). TGF-β1 is increased in experimental and human hepatic fibrosis (97, 213). Upregulation of TGF-β1 in activated stellate cells occurs through multiple mechanisms. Factors including Sp1 (272) and KLF6 (306) transactivate the TGF-β1 promoter, which has multiple GC boxes, the promoter element responsive to these transcription factors. There are also multiple mechanisms mediating the activation of latent TGF-β1, including cell surface activation following binding to cell-surface mannose-6-phosphate/IGF-II receptor (117) or binding to a number of proteins secreted by stellate cells (209), such as α2-macroglobulin (9), decorin, and biglycan (417). Recent studies suggest the important role of local plasminogen activator (PA)/plasmin in activating latent TGF-β1 (255, 460, 461). This mechanism is regulated by metabolites of RA. The signaling of TGF-β1 in rat stellate cells involves the activation of Ras, Raf-1, MEK, and mitogen-activated protein (MAP) kinase (522). The roles of Smads have been extensively explored in recent years in stellate cells (71,
earlier studies had suggested CTGF is regulated by TGF-
the hepatocytes may be even more important (214). While
the source of this cytokine in the liver (475, 477); however,
CTGF is strongly expressed in stellate cells, the more recent report indicates that its
expression in stellate cells is TGF-β and Smad 2/3 independent, in contrast to hepatocytes where CTGF regulation is TGF-β dependent (214). These findings are particularly interesting in emphasizing that the regulation of the
same cytokine may be completely divergent between two
resident liver cell populations, pointing to the potential of cell- and pathway-specific inhibition of a factor that is
widely expressed (214).

Endothelin-1 (ET-1) was originally identified as a
potent vasoconstrictor produced mainly by endothelial
cells (711). Stellate cells are a major source as well as a
target of this cytokine during liver injury (286, 289, 376,
377, 495, 535, 539, 545). ET-1 has a prominent contractile
effect on stellate cells and myofibroblasts, which may contribute to portal hypertension in the cirrhotic liver
(309, 393, 534). In addition, ET-1 promotes the prolifera-
tion of early-cultured stellate cells, whereas it inhibits
fully activated ones (i.e., cultured for more than 1 wk)
(544). These responses are mediated through ET-1 recep-
tors (see sect. vE). Interestingly, stellate cells also pro-
duce nitric oxide (NO), a physiological antagonist to ET-1
(540). NO production is attributable to the activity of the
inducible form of NO synthase in stellate cells (540) and
is highly responsive to proinflammatory cytokines or en-
dotoxemia (36, 238, 483, 641, 643). NO may play a role in the
maintenance of microcirculation during liver injury.

Stellate cells also secrete cystatin C (212), a serum
protein filtered by the kidney and used as a sensitive
marker of glomerular filtration rate (621). Interestingly,
the blood levels of cystatin C predict risk of death from a
myocardial infarction or cardiovascular deaths, for un-
clear reasons (600).

E. Biology of Membrane and Nuclear Receptors

1. Biology of membrane receptors

Cytokines regulate stellate cell biology by specific
and high-affinity binding to their membrane receptors. So
far, several cytokine receptors have been identified in
either quiescent or activated stellate cells (see Table 1).
In addition, other receptors such as integrin, whose
ligands are not cytokines, are also important in regu-
lating stellate cell behavior. The generation of a mono-
clonal antibody to membrane proteins or synthetic car-
riers that mimic the receptor-binding domains of key
cytokines may facilitate the development of stellate
cell-specific targeting in vivo for diagnostic and thera-
petic applications (45, 139).

PDGF receptor was the first membrane receptor
identified in stellate cells. It is composed of α- or β-sub-
units as either homodimers or heterodimers. In rat stel-
late cells, the β-subunit is the predominant isoform (233,
486, 493, 496), whereas in human stellate cells, both α-
and β-subunits are detectable (698). Activated PDGF re-
cipient recruits the signaling molecule Ras, followed by
activation of ERK/MAP kinase pathway (91, 163). In ad-
dition, phosphoinositol 3-kinase (PI 3-kinase) and STAT-1
also contribute to PDGF signaling in stellate cells (291,
390). There is also evidence that PDGF signaling requires
NADPH oxidase (2). The presence of PDGF receptors has
been exploited by developing targeting reagents intended
to direct therapies directly to stellate cells (3, 46).

TGF-β receptors have been extensively characterized
in stellate cells (71, 213, 259, 693). All three forms of
TGF-β receptors, types I, II, and III (betaglycan), are
expressed. TGF-β1 binding and responsiveness are
greatly enhanced during activation in vivo and in vitro
(176) and induced by corticosteroids (697). A complex
signaling pathway downstream of TGF-β receptors has
been uncovered in stellate cells involving classical TGF-β
intracellular effectors, the Smad proteins, in particular
Smads 1, 2, and 3 (71, 259, 693, 698) and the inhibitor of
differentiation (Id) protein (698). Interestingly, Smad sig-
aling evolves with stellate cell activation (128, 130, 357)
and plays different roles during progressive cellular activa-
tion (656). Recent findings suggest that altered Smad
signaling may underlie the stellate cell’s response to ma-
trix stiffness (694). An endogenous antagonist to Smad-2/3
-mediated stellate cell activation is Smad7 (129, 324).
Antagonism of TGF-β signaling is an important and prom-
ising approach to antifibrotic therapy, either through ad-
ministration of N-acetyl cysteine (325), Smad7 (129), sol-
uble TGF-β receptors (197, 657), interferer-γ (695),
bone morphogenic protein-7 (729), or a variety of other
means (359).

CTGF receptors expressed by stellate cells include
αvβ3-integrin (185) and the low-density lipoprotein recep-
tor-related protein (LRP), which is a heparin-dependent
adhesion receptor (CTGF) (186). The effects of ET-1 are
mediated through two G protein-coupled receptors. Re-
cipient types A and B have been identified in both quies-
cent and activated stellate cells (245, 289, 535, 537). The
relative prevalence of ET A and ET B receptors changes...
with stellate cell activation (495). The ET \textsubscript{B} receptor is the predominant mediator of stellate cell contraction (535) and can be antagonized by a Rho-ROCK inhibitor (290). In addition, the proliferative effect of ET-1 in quiescent stellate cells is mediated through the ET \textsubscript{A} receptor (495), whereas its growth inhibitory effect in activated stellate cells is mediated through the ET \textsubscript{B} receptor (377).

In view of their contractile activity and potential role in vasoregulation, it is not surprising that stellate cells express a large number of other receptors, cytoskeletal proteins, and intracellular mediators that either enhance or antagonize cellular contraction (see Ref. 534 for review). Mediators of contraction include ROCK (290), Rho GTP binding proteins (285, 715), a sodium-calcium exchanger that is induced during cellular activation (432), and eicosanoids (287). Relaxants include NO (342), C-type and atrial natriuretic peptides (205, 637), which regulate calcium signaling following interaction with its receptor, as well as carbon monoxide generated by stellate cell-derived heme oxygenase (350, 623).

Induction of receptors for VEGF has been identified during stellate cell activation both in vivo and in culture (10, 12, 109, 400). VEGF receptor upregulation is associated with enhanced mitogenesis in response to VEGF, which is further synergized by bFGF. Because VEGF plays a critical role in angiogenesis, this finding suggests that stellate cells may be involved in typical “angiogenic” responses, broadening their potential roles in both wound healing and tumor formation (343).

Stellate cells also express the receptor for thrombin, a serine protease derived from prothrombin (388), which may stimulate migration of active cells (202). The binding of thrombin to its receptor leads to cellular proliferation and increased production of MCP-1. In addition, other proteinase receptors are expressed on stellate cells, indicating the presence of complex regulation of their multiple functions (38, 78, 154–156, 180, 494).

In addition to receptors for cytokines, other membrane receptors have also been characterized in stellate cells. Integrins are a special type of membrane receptor that transduces signals from extracellular matrix to cells (232, 418). They are heterodimeric transmembrane proteins composed of α- and β-subunits whose ligands are matrix molecules rather than cytokines. Several integrins, disintegrins, related molecules, and their downstream effectors have been identified in stellate cells, including α\textsubscript{1β1}, α\textsubscript{2β1}, αβ\textsubscript{4}, αδβ\textsubscript{1}, α\textsubscript{β}, and integrin-linked kinase (92, 140, 178, 185, 220, 269, 302, 339, 347, 392, 408, 447, 494, 508, 509, 593, 694, 735, 736, 738). In particular, integrin ligands contain an arginine (Arg)-glycine (Gly)-aspartate (Asp) tripeptide sequence. The common presence of Arg-Gly-Asp (RGD) within many integrin ligands has raised the possibility of using competitive RGD antagonists to block integrin-mediated pathways in fibrogenesis (268). Another matrix binding mole-

ucle, CD44, the hyaluronic acid receptor, has been identified on activated stellate cells (301), which promotes cellular migration.

An unusual family of tyrosine kinase receptors called “discoidin domain receptors” (DDR) has been uncovered, whose ligands are fibrillar collagens rather than growth factors (334). The intriguing identification of DDR mRNA in activated stellate cells (251, 382, 456, 463, 704) raises the possibility that this receptor may mediate interactions between stellate cells and the surrounding interstitial matrix, particularly as it accumulates in progressive liver injury.

Stellate cells express cannabinoid receptors, molecules that evolved as a component of an endogenous cannabinoid signaling pathway (123, 274, 332, 727). Endogenous cannabinoids can provoke stellate cell death via necrosis involving mitochondrial reactive oxygen species (603–605). Initial studies of the role of cannabinoids in hepatic fibrosis had yielded apparently paradoxical findings, which have largely been reconciled now that the divergent effects on liver fibrosis of the two cannabinoid G protein-coupled receptors (CB1 and CB2) have been clarified. Studies in human stellate cells demonstrate that activation of CB2 is anti-fibrogenic (279), and stimulation of cultured stellate cells with an endogenous cannabinoid, anandamide, provokes stellate cell death, albeit through a CB2 ligand-independent pathway (605). In experimental models of liver injury, CB1 receptor is induced primarily in hepatic stellate cells as they activate into myofibroblasts during liver injury (279, 638). Antagonism of this receptor in an acute model of injury due to CCl\textsubscript{4} or in isolated cells led to decreased expression of TGF-β, the most potent fibrogenic cytokine; this reduces cellular proliferation and increases myofibroblast apoptosis, both of which would effectively reduce fibrosis. In addition, stellate cells from CB1 receptor −/− mice display reduced phosphorylation of ERK and Akt, which explains the cells’ decreased cellular growth and survival, respectively (638).

Studies of weight regulation and appetite have uncovered complex signaling pathways both in the brain and in the periphery, especially the liver. In particular, adipokines, or hormones produced by adipose (among other sources), are emerging as major mediators of hepatic metabolism, injury, and fibrosis (106, 127, 386). Stellate cells express leptin (501) and its receptors (253, 254, 468, 565), which mediate a range of biologic activities, including fibrogenesis (88, 105, 566), in part by enhancing TGF-β (636), cell survival (505), inflammation (5, 252) and by repressing metalloproteinase expression (88). Leptin’s natural counterregulator, adiponectin, is also expressed by stellate cells (701) and is antifibrotic (106, 127, 282, 386).

Hepatic stellate cells express P2Y receptors, which link extracellular ATP to inositol trisphosphate-mediated...
cytosolic calcium signaling (132, 328). Stellate cells only express the type I inositol trisphosphate receptor, which shifts into the nucleus upon cellular activation (328), suggesting a novel pathway for regulation of fibrogenesis. Other nucleotide receptors have also been identified on stellate cells (634).

Adenosine receptors are expressed by stellate cells, and they provide at least two signals, the stimulation of fibrosis and the provision of a “stop signal” as stellate cells reach sites of injury following migration (228). Antagonism of adenosine signaling by caffeine through its phosphodiesterase antagonism could explain the protective effect of coffee drinking on liver injury and the development of hepatic fibrosis in large epidemiologic surveys (99, 315, 556, 557).

Activity of the hedgehog (Hh) signal pathway has been identified in stellate cells (602). The presence of this pathway is quite interesting, since it was initially described in the development of Drosophila as a segment polarity gene required for embryonic patterning and is often reactivated in tumors (345, 630). Hh signaling contributes to stellate cell activation (602), but an even more exciting issue is whether this pathway also contributes to the potential pleuripotency of stellate cells, as suggested by their expression of CD133 (326) (see sect. V).

Chemokine receptors are a family G protein-coupled receptor mediating a range of cellular activities including leukocyte chemotaxis, angiogenesis, myofibroblast proliferation and migration, neoplasia, and the response to viral antigens (101, 296, 385). They are particularly attractive therapeutic targets because their structure makes them inherently “targetable” (196). Chemokine receptors identified thus far on stellate cells include CCCR5, whose ligand, RANTES, is induced by NFκB signaling, and stimulates stellate cell migration and proliferation (580) (see Fig. 5). The cells also express CXCR3, which can activate Ras, Akt, and PI 3-kinase, also leading to migration and proliferation (67). As with virtually all cytokine pathways in stellate cells, components of autocrine signaling are present, although in the case of MCP-1, its conventional receptor, CCR2, does not mediate MCP-1’s effects, suggesting the presence of an as-yet-undefined receptor (394).

As noted in sect. V, stellate cells are assuming an increasingly central role in inflammatory signaling. In addition to chemokine receptors, they express CD40 (581), which provides an important functional bridge to immune cells, which express CD40 ligand. CD40L engagement by stellate cells stimulates production of MCP-1 and IL-8, which are both proinflammatory signals.

Angiotensin receptors have assumed vital importance in stellate cell biology based both on their key role in cellular activation and on mounting evidence that their antagonism represents a very promising antifibrotic strategy (37). Activated human and rodent stellate cells express all components of the renin-angiotensin system including angiotensin II and its cognate receptor (38, 688, 690). Moreover, infusion of angiotensin II induces stellate cell activation and inflammation in rats (36). The effects of angiotensin are mediated through NADPH oxidase, a multiprotein complex that generates reactive oxygen species (39, 120). Within this complex, only rac1 has been identified as a functionally active component (120), as underscored by a transgenic mouse model in which overexpression of rac1 in stellate cells amplified injury and fibrosis (104). Most importantly, antagonism of angiotensin signaling, either by angiotensin converting enzyme inhibitors, or by receptor antagonists, is antifibrotic in animal models (278, 515, 689), and in a retrospective human study of patients following liver transplantation (527). As a result of this promising animal and retrospective human data, a controlled prospective trial of angiotensin II type I receptor antagonist, irbesartan, is underway in France (http://clinicaltrials.gov/ct/show/NCT00265642?order=2).

Although not a cytokine, ferritin, an iron binding protein, also binds specifically to high-affinity cellular receptors on stellate cells (516). Activation-dependent binding of ferritin is followed by internalization and is dependent on the H subunit (516). While these findings are intriguing, it is uncertain whether ferritin binding is functionally related to stellate cell activation.

A number of other membrane receptor systems have been identified on stellate cells, including those for hydroxysteramine (351), somatostatin (611), catecholamines (455, 560), endogenous opioids (137), serotonin (554), and oxidized LDL (CD36) (576). Stellate cells also express receptors for advanced glycation end products (RAGE) (150), a member of the immunoglobulin superfamily. Consistent with their neural phenotype, stellate cells express neurotrophin receptors (95). Interestingly, serotonin receptors, in particular SSR2, SSR3, and SSR5 (611), are induced during stellate cell activation (473, 554). These receptors downregulate cellular activation (337, 524), suggesting that octreotide and other somatostatin analogs merit exploration as antifibrotic agents.

2. Biology of nuclear receptors

A dramatic increase in knowledge about intracellular nuclear receptors has greatly benefited our understanding of stellate cell biology. These receptors are members of the nuclear hormone receptor superfamily (659). In the presence of their cognate ligands, they translocate to the nucleus and act as transcription factors. Not only has information emerged about retinoid receptors in stellate cells, but also about the entire nuclear receptor family, in particular peroxisome proliferators activated receptors (PPARs), as well as the farnesoid X receptor (FXR).
Retinoid receptors have been extensively explored in stellate cells given their important role in retinoid metabolism. However, no clear, coherent model for retinoid receptors in this cell type has emerged, and some of the data are contradictory. Stellate cells express retinoic acid receptors (RAR) α, β, and γ (175, 692) as well as retinoid X receptors (RXR) α and β, but not γ (659).

In culture, RXR-α is the dominant receptor (659), but stellate cells express all six major isoforms (RAR-α, -β, -γ and RXR-α, -β, -γ)(671) and modulate a number of target genes, including cellular retinol binding protein (CRBP) (671) and collagen I (684). Natural and synthetic retinoids elicit a range of activities (236): synthetic RXR agonists and 9-cis-RA downregulate stellate cell proliferation and synthesis of collagen I and fibronectin. In contrast, all-trans-RA and RAR agonists both reduce collagen I, collagen III, and fibronectin but have no effect on stellate cell proliferation. Finally, RAR-specific antagonists provoke stellate cell mitogenesis. In cultured stellate cells, an increase in 9,13-di-cis-RA transactivates RAR-α and stimulates plasminogen activation and TGF-β-dependent procollagen synthesis (461). These findings are paralleled in vivo in an experimental model of porcine serum-induced steatosis (616). Surprisingly, however, FXR is also expressed by stellate cells, where it has an antifibrotic action (655), further implicating this cell type as a participant in lipid homeostasis and inflammation (42), has also been identified as a potential role in vitamin D homeostasis and responsiveness. In support of this prospect, 1,25-dihydroxyvitamin D₃ is mitogenic in cultured stellate cells (356).

Estrogens, in particular, 17β-estradiol (358) and estradiol (598, 703, 713), are antifibrotic in liver, which may contribute to the decreased risk of fibrosis progression in females compared with males (57, 124, 686). Indeed, in cultured stellate cells, estradiol inhibits activation through an antioxidant effect, whereas this activity is antagonized by progesterone (265); estradiol's effect may be mediated by estrogen receptor (ER)-β, since stellate cells express ER-β but not ER-α (598).

Glucocorticoid receptor is also expressed by stellate cells (511), but its contribution to stellate cell behavior has not been explored.

The FXR is a major regulator of bile flow by stimulating expression of several key genes involved in cellular bile acid export (107, 531), and its therapeutic activation may become a major advance in the management of cholestasis (616). Surprisingly, however, FXR is also expressed by stellate cells, where it has an antifibrotic activity through upregulation of its target molecule SHP (155, 156). FXR ligands suitable for human administration have been developed, and clinical trials for cholestatic liver diseases are anticipated, with antifibrotic trials likely to follow.

Liver X receptor, a nuclear receptor that is a nutritional sensor of cholesterol metabolism and major regulator of lipid metabolism, lipid metabolism, glucose homeostasis, and inflammation (42), has also been identified in stellate cells (655), further implicating this cell type as a participant in lipid homeostasis.

F. Adipogenic Features

The extensive characterization of signaling pathways for leptin, adiponectin, and PPAR-γ in stellate cells has highlighted remarkable parallels between this cell type...
and adipocytes. This relationship has been emphasized in studies by Tsukamoto and co-workers (594, 653, 655), underscoring that the transcriptional program required for adipocyte differentiation is nearly identical to that required for maintaining stellate cells in their quiescent, vitamin A-storing phenotype. In particular, forced expression of either PPAR-γ or sterol regulatory element binding protein 1c (SREBP-1c), two key regulators of adipogenesis, or incubation of stellate cells with an “adipogenic” mix of soluble factors, drive the cells towards a quiescent phenotype (594, 653). In contrast, two anti-adipogenic signals, TNF-α and Wnt, promote activation (655). Stellate cells also express a number of other adipogenic transcription factors, including CCAAT/enhancer-binding protein (C/EBP)α, C/EBPβ, C/EBPδ, PPAR-γ, liver X receptor-α, SREBP-1c, and adipocyte-specific genes (594), as well as adipokines including leptin and adiponectin (127, 386).

G. Detoxifying and Antioxidant Enzymes, pH Regulation, and Generation of Oxidant Stress

Several enzymes involved in both intermediary metabolism and detoxification of ethanol and xenobiotics have been identified in stellate cells. Stellate cells contain alcohol (93) and acetaldehyde (710) dehydrogenase, although it is unlikely that the cell type plays a significant role in ethanol detoxification based on its relatively low numbers compared with hepatocytes. However, the cells may be responsive not only to lipid peroxides and hydrogen peroxide generated during ethanol metabolism (98, 207, 443, 445, 446), but also to acetaldehyde adducts, which stimulate the secretion of chemokines (299).

Stellate cells express several P-450 enzymes, specifically CYP2C11, 3A2, 2D1, Cyp2S1 (383), and CYP3A (480). Interestingly, activation of these enzymes decreases during culture-induced activation (707), possibly rendering stellate cells more sensitive to either xenobiotics or oxidant stress.

The α-, μ-, and π-isofoms of glutathione S-transferase have been identified in stellate cells, both by enzymatic assay as well as Northern and Western blots (344); these enzymes are important for detoxification of xenobiotics and the response to oxidant stress, a finding with implications for both normal liver function as well as the response to injury (122). Activated stellate cells also express stellate cell activation associated protein (STAP), an endogenous peroxidase catabolizing hydrogen peroxide and lipid hydroperoxides (288). Stellate cells contain glutathione synthase (373), as well as the mRNA for the glutathione peroxidase I, the selenium-dependent isofom (335), which is induced during stellate cell activation in vivo. Glutathione levels may in fact discriminate between oxidative stress and activation due to TGF-β1 (119). On the other hand, manipulation of glutathione stores in stellate cells has no effect on cellular activation (373). Interestingly, whereas culture-induced stellate cell activation leads to accumulation of glutathione, activation in vivo does not (374), highlighting one of the rare examples where culture-induced activation pathways are different from those associated with stellate cell activation in vivo. Finally, addition of N-acetyl-L-cysteine (NAC) to stellate cells, which restores cellular glutathione levels, leads to stellate cell cycle arrest and induction of p21 (302).

Stellate cells also have tightly regulated systems for monitoring cellular pH (125), which are closely linked to cellular activation. Specifically, the Na+/H+ exchanger is the main intracellular (pH i) regulator in rat stellate cells, and stellate cell activation is associated with an increase in pH, and in PDGF-stimulated activity of the Na+/H+ exchanger (125, 626). Inhibition of this transporter by amiloride (125) has led to studies in animal models demonstrating an antifibrotic effect of antagonizing this transporter (47).

There is mounting evidence for a key role of NADPH oxidase (NOX) in mediating several pathways critical to stellate cell activation, including responses to angiotensin II and PDGF, apoptosis of cellular debris, and generation of oxidant stress (120). Specifically, stellate cells express key components (p22phox, gp91phox, p47phox, and p67phox) of a nonphagocytic form of NADPH oxidase that produces superoxide (2). This enzyme is induced during stellate cell activation and generates superoxide upon engagement of ANG II with its receptors (39). ANG II signaling leads to phosphorylation of the p47 subunit of NOX, increased superoxide production, and stellate cell activation, responses which are blunted in p47−/− mice (39). These animals have reduced fibrosis after liver injury due to bile duct ligation, attesting to the biological relevance of this pathway. Interestingly, phagocytic activity of stellate cells towards apoptotic bodies is also linked to NOX induction, with increased oxidative stress; this response is inhibited by the NOX inhibitor diphenylene iodonium (DPI) (730). Finally, NOX also mediates downstream effects of PDGF receptor signaling, and DPI blocks proliferative effects of PDGF (2).

H. Transcriptome and Proteome Analyses

The development of array technologies to characterize patterns of gene (i.e., mRNA) expression from the entire transcriptome has provided a valuable tool for uncovering new information about cellular and molecular biology of liver (23). In general, microarrays can be used clinically to define features of disease, forecast prognosis, and predict response to therapies. While in the clinical setting arrays have been primarily applied to the management of cancer, the technology is proving equally valuable in defining cellular and tissue responses in nonmalignant...
diseases, including fibrosis and tissue repair. In particular, cDNA microarrays have been used to interrogate stellate cells in the hope of uncovering new insights into the cell’s complex biology. This approach offers several benefits for the study of stellate cells: 1) to uncover novel genes not previously ascribed to these cells; 2) to define pathways or clusters of gene expression that underlie phenotypic transitions of stellate cells, in particular stellate cell activation associated with hepatic fibrogenesis; 3) to validate stellate cell culture models by demonstrating similar patterns of gene expression as cells in vivo; and 4) to reveal potential targets of antifibrotic therapies.

By applying these criteria, the mountain of information typically provided by a microarray experiment can be placed in some rational context (573). While the technology continues to evolve, current methods utilize platforms (i.e., silicon chips) that contain the entire transcriptome, although they do not routinely distinguish alternative mRNA splice forms of genes (111), which is an increasingly important mechanism of genetic diversity (187, 614). For each potentially new transcript, it is also essential to validate the reported expression or change using a more direct method, typically quantitative real-time PCR or related methods including Northern or Western hybridization. With continued standardization of microarray methods and publication requirements that obligate investigators to make their raw data available publicly (131, 136, 247), array results can be used by all investigators to either validate findings or define new research questions, thereby accelerating progress considerably.

Studies utilizing gene array methodologies have begun to apply each of these four benefits to stellate cell analysis, using either human or rodent cells or immortalized cell lines. For example, an unanticipated role of Wnt signaling was uncovered by a comparison of quiescent rat primary (early culture) stellate cells from normal liver, to cells activated by growth in culture for 8–14 days (273). Not only was Wnt signaling induction validated directly, but the array methodology also confirmed the induction of Wnt target genes, which were complemented by evidence of Wnt induction in vivo. Similarly, in an analysis of activated stellate cells from mouse using serial analysis of gene expression (SAGE), a technique conceptually similar to subtractive hybridization (667), a novel intracellular mediator of bone morphogenetic protein, gremlin, was identified (65). Novel genes have also been uncovered in a recent cDNA microarray study of activated rat stellate cells, including the chemokines CCL6, CXCL14; proteases MMP-10 and MMP-23; neural markers neutrotrimin, neurexin-1, and synaptotagmin-9; fat metabolism enzyme LRAT; cell surface receptors adenosine receptor 2a, GRP 91; and cytoskeletal proteins anillin, plexin, and C1 (121). A similar approach was employed in a study analyzing gene expression patterns in human stellate cells isolated from human fibrotic liver, compared with normal primary stellate cells (561). In another report comparing stellate cells from normal rat liver, cirrhotic liver, and normal cells activated by growth on plastic, there were distinct differences between normal cells and those activated by plastic, but fewer differences between stellate cells from normal versus cirrhotic liver (275).

Recently, gene expression patterns from stellate cells isolated from normal rat liver were compared with rats with fibrosis from either CCl4 or bile duct ligation, or to normal cells activated by growth on plastic (121). Expression profiles in stellate cells between the two fibrotic models were remarkably similar but differed substantially from ultrapurified (i.e., using flow cytometry) culture-activated stellate cells. However, when stellate cells were isolated using standard gradient methods alone, which typically contain ~5% of other nonparenchymal cells (especially Kupffer cells), the gene expression pattern much more closely resembled activated stellate cells from fibrotic liver. This might suggest that the most widely used stellate cell isolation methods with gradient centrifugation alone are most relevant to understanding the biology of stellate cells in vivo. Studies have also been conducted to identify genes associated with activation of mouse stellate cells, revealing additional transcripts that regulate a range of cellular functions, several of which were not anticipated (360).

In a microarray study of human stellate cells after extended culture, cells became senescent and switched from a primarily fibrogenic to an inflammatory phenotype, with decreased proliferation gene expression and increased apoptosis (575). Those inflammatory genes included IL-8, cyclooxygenase 2, superoxide dismutase, and ICAM-1, among others (575). There were also cytoskeletal rearrangements and reduced expression of fibrogenic mRNAs. However, findings were not validated directly to demonstrate that the phenotypes described in culture had a counterpart in vivo.

Array methodology has also been used to define pathways and target genes affected by a specific stimulus. For example, a study in the human LX-2 stellate cell line identified genes associated with the response to hypoxia, revealing transcripts associated with kinase activation, cellular respiration, membrane transport, transcriptional regulation, and protease activities, among others (596). Array has also been used extensively to validate that the gene expression patterns of immortalized stellate cell line resemble those of primary cells. Such studies have analyzed a human line expressing ectopic telomerase (574), as well as human stellate cells immortalized with either the SV40 T antigen or low-serum conditions (704).

In addition to analyses of isolated stellate cells, a number of studies have characterized gene array patterns from whole liver to assess evolution of mRNA expression during disease, primarily HCV. In part, these studies are
performed to identify gene clusters that may reveal novel pathways of disease or predict clinical outcomes. While this approach cannot directly ascribe gene expression to stellate cells, in many cases their contribution to the pool of expressed mRNAs can be inferred, but must be validated using in situ methods or analysis of isolated cells. Nonetheless, at least six studies in humans (22, 53, 338, 591, 592, 610) and one in rats (506) have explored this question, with interesting results. For example, one study of HCV-infected livers (591) identified mRNAs for the fibrosis-associated protein extracellular matrix metalloproteinase inducer (EMMPRIN) (CD147) and discoidin domain receptor-1 (CD167), which had not previously been identified in liver, prompting the need to explore these transcripts in isolated stellate cells. Another study indicated that genes involved in matrix turnover and immune response may be critically associated with the transition from mild to moderate fibrosis (22), highlighting the key role of stellate cell behavior in this transition. Similarly, an analysis of human livers with HCV uncovered an abundance of transcripts associated with inflammation and matrix turnover in early fibrosis, whereas in advanced fibrosis genes associated with cellular proliferation predominated (338). Yet another study in whole liver of patients with HCV reported a predominance of transcription factors that are regulated by interferon (53). Finally, in a study of patients who had serial liver biopsies following liver transplantation for HCV (610), discrete gene expression patterns emerged that predicted fibrosis progression, including transcripts clearly associated with activated stellate cells/myofibroblasts, for example, collagen XII, a calcium channel, and two myosin polypeptides and a myosin binding protein. This study is particularly important because gene expression patterns were compared in samples from the same patients during disease progression, beginning with a normal donor organ at the time of transplant.

Proteomics technology remains a rapidly evolving approach to probe cell and tissue function, including liver, and offers the advantages of identifying different posttranslational modifications, including phosphorylation and glycosylation, as well as uncovering new proteins or protein isoforms (23, 484, 613). A number of studies have used proteomics to characterize proteomic patterns in whole liver of rodents (161, 705) and either human liver (415, 498), or serum (231), but only one study to date has specifically characterized the proteome of quiescent and activated stellate cells. Bach Kristensen and colleagues (27) described over 300 stellate cell proteins, including a novel globin molecule, STAP or cytoglobin, which has been characterized in detail in follow-up studies (19, 434). In addition, they identified 26 other proteins regulated similarly in culture and in vivo, including upregulation of calcyclin, calgizzarin, and galectin-1 as well as downregulation of liver carboxylesterase 10 and serine protease inhibitor 3 (27). These results demonstrate the promise of using proteomics to uncover information complementary to that obtained by cDNA microarray.

Among proteomics studies of whole liver reported to date, the vast majority of proteins identified are derived from hepatocytes, as their total protein content vastly exceeds proteins derived from stellate or other nonparenchymal cells. Nonetheless, some stellate cell-related proteins may emerge from this approach.

In addition to genomics and proteomics, a whole range of other “omics” technologies are being developed (333, 426). The term omics refers to the analysis of different classes of molecules, processes, or functions and structures as systems (297). Currently, these include glycomics, kinomics, metabolonomics nutrigenomics, toxicogenomics, and ecotoxicoproteomics; it would seem inevitable that these technologies will be applied to stellate cell biology. To date, however, only glycomics has been studied in relation to hepatic fibrosis to uncover patterns of protein glycosylation in serum that correlate with the stage of disease (79).

VI. STELLATE CELL RESPONSES IN LIVER INJURY AND REPAIR

A. Stellate Cell Activation: Features, Regulation, and Reversibility

The clarification of stellate cell responses in hepatic injury and repair has been a significant turning point in understanding the basis of hepatic fibrosis. In particular, the identification of stellate cell activation as a key event in fibrogenesis has provided an important framework for conceptualizing the liver’s response to injury. As noted in section I, this review is not intended to focus primarily on mechanism of hepatic fibrosis, but rather on broader aspects of stellate cell behavior. The reader is referred to many recent reviews for more comprehensive updates on fibrosis pathogenesis (35, 165, 167, 213, 313, 363).

Stellate cell “activation” refers to the conversion of a resting vitamin A-rich cell to one that is proliferating, fibrogenic, and contractile. While it is increasingly clear that other mesenchymal cell populations also contribute to extracellular matrix accumulation, stellate cell activation remains the most dominant pathway leading to hepatic fibrosis (see Fig. 6). Moreover, stellate cell activation represents a continuum, such that early changes in cellular phenotype may be distinct from those occurring with progressive injury and activation in terms of growth characteristics, response to soluble mediators, inflammatory signaling, and apoptotic potential (128, 204, 210, 504, 552, 575). Finally, the paradigm of activation of resident mesenchymal cells into fibrogenic myofibroblasts extends to many tissues beyond liver (243).
Activation consists of two major phases: initiation and perpetuation, followed by resolution of fibrosis if injury subsides (see Fig. 7).

Initiation (also called a “preinflammatory stage”) refers to early changes in gene expression and phenotype that render the cells responsive to other cytokines and stimuli. Initiation results mostly from paracrine stimulation, primarily due to changes in surrounding extracellular matrix, as well as exposure to lipid peroxides and products of damaged hepatocytes.

Perpetuation results from the effects of these stimuli on maintaining the activated phenotype and generating fibrosis. Perpetuation involves autocrine as well as paracrine loops. It is comprised of several discrete responses including proliferation, contractility, fibrogenesis, matrix degradation, retinoid loss, and inflammatory cell infiltration.

Resolution of fibrosis refers to pathways that either drive the stellate cell to apoptosis, or contribute to their reversion to a more quiescent phenotype.

**FIG. 6.** Sources of myofibroblasts in liver injury. Multiple sources of fibrogenic myofibroblasts are likely in liver injury depending on the site and nature of the injury. While resident stellate cells appear to be the most likely source, periportal fibroblasts may be especially prominent in biliary injury, whereas bone marrow and possible epithelial-mesenchymal transition may contribute as well.

**FIG. 7.** Pathways of stellate cell activation and resolution. Following liver injury, hepatic stellate cells undergo “activation,” which connotes a transition from quiescent vitamin A-rich cells into proliferative, fibrogenic, and contractile myofibroblasts. The major phenotypic changes after activation include proliferation, contractility, fibrogenesis, matrix degradation, chemotaxis, retinoid loss, and WBC chemoattraction. Key mediators underlying these effects are shown. The fate of activated stellate cells during resolution of liver injury is uncertain but may include reversion to a quiescent phenotype and/or selective clearance by apoptosis. [From Friedman (165).]
1. Initiation

The earliest changes observed during stellate activation result from paracrine stimulation by all neighboring cell types, including sinusoidal endothelium, Kupffer cells, hepatocytes, and platelets. As noted above, early injury to endothelial cells stimulates production of cellular fibronectin, which has an activating effect on stellate cells (270). Endothelial cells are also likely to participate in conversion of TGF-β from the latent to active, profibrogenic form. Platelets are another important source of paracrine stimuli, including PDGF, TGF-β, and EGF (28).

Kupffer cell infiltration and activation also contribute to stellate cell activation. Kupffer cells stimulate matrix synthesis, cell proliferation, and release of retinoids by stellate cells through the actions of cytokines (especially TGF-β) and reactive oxygen intermediates/lipid peroxides (55).

Hepatocytes are a potent source of fibrogenic lipid peroxides, although effects on stellate cell collagen synthesis and proliferation may be dose dependent (450). Hepatocyte apoptosis following injury also promotes stellate cell initiation through a process mediated by Fas (83, 84). This process may involve the TNF-related apoptosis-inducing ligand (TRAIL) (83, 84). Whereas hepatocyte necrosis associated with lipid peroxidation is considered a classical inflammatory and fibrogenic stimulus, recent findings also implicate apoptosis, or programmed cell death, in the fibrogenic response. Apoptotic fragments released from hepatocytes are fibrogenic towards cultured stellate cells (85) and activate Kupffer cells (82) (see sect. VI). Also, Fas-mediated hepatocyte apoptosis is fibrogenic in vivo in experimental animals (84).

The cytochrome CYP2E1 plays an important role in the generation of reactive oxygen species that stimulate hepatic stellate cells (443). Cultured hepatic stellate cells grown in the presence of the HepG2 cell line expressing CYP2E1 (E47 cells) leads to increased production of collagen, an effect prevented in the presence of antioxidants or a CYP2E1 inhibitor (443). These data suggest that the CYP2E1-derived reactive oxygen species are responsible for the increased collagen production. In similar experiments using cocultured hepatic stellate and E47 cells, the addition of arachidonic acid plus ferric nitrotriacetate (agents that potentiate oxidative stress) further induced collagen synthesis (444). These findings may help to explain the pathogenesis of liver injury in alcoholic liver disease since CYP2E1 is alcohol inducible.

2. Perpetuation

Perpetuation of stellate cell activation involves at least seven discrete changes in cell behavior: proliferation, chemotaxis, fibrogenesis, contractility, matrix degradation, retinoid loss, and WBC chemoattractant/cytokine release. The net effect of these changes is to increase accumulation of extracellular matrix. As an example, proliferation and chemotaxis lead to increased numbers of collagen-producing cells. Cytokine release by stellate cells can amplify the inflammatory and fibrogenic tissue responses, and matrix proteases may hasten the replacement of normal matrix with one typical of the wound “scar.”

A) Proliferation. PDGF is the most potent stellate cell mitogen identified (68, 486). Induction of PDGF receptors early in stellate cell activation increases responsiveness to this potent mitogen (702). Downstream pathways of PDGF signaling have been carefully characterized in stellate cells and include PI 3-kinase, among others (340, 494).

In addition to proliferation, PDGF stimulates Na+/H+ exchange, providing a potential site for therapeutic intervention by blocking ion transport (126). Other compounds with mitogenic activity in stellate cells and a potential role in fibrogenesis include vascular endothelial cell growth factor (720), thrombin and its receptor (388, 391), EGF, TGF-α, keratinocyte growth factor (620), and bFGF (724). Signaling pathways for these and other mitogens have been greatly clarified in stellate cells, offering many potential sites for therapeutic intervention (see Ref. 494).

B) Chemotaxis. Stellate cells can migrate towards cytokine chemoattractants (369, 385, 494), explaining in part why stellate cells align within inflammatory septae in vivo. A number of chemoattractants have been identified, prominent among which are PDGF (250, 310), MCP-1 (394), and CXCR3 (67). In contrast, adenosine (228) blunts chemotaxis and may immobilize cells once they reach the site of injury (see also sect. vD). The mechanical features of stellate cell chemotaxis have recently been explored, revealing that PDGF-stimulated chemotaxis is associated with cell spreading at the tip, movement of the cell body towards the stimulant, and retraction of trailing protrusions associated with transient myosin phosphorylation (414).

C) Fibrogenesis. Stellate cells generate fibrosis not only by increased cell numbers, but also by increasing matrix production per cell. The best-studied component of hepatic scar is collagen type I, the expression of which is regulated both transcriptionally and posttranscriptionally in hepatic stellate cells by a growing number of stimuli and pathways. A detailed review of collagen gene regulation in stellate cells is beyond the focus of this review, but several recent references are recommended (7, 188, 257, 258, 260, 354, 528, 617–619, 652).

The most potent stimulus for production of collagen I and other matrix constituents by stellate cells is TGF-β, which is derived from both paracrine and autocrine sources (see Refs. 71, 213, 259 for reviews). Signals downstream of TGF-β include a family of bifunctional molecules known as Smads, upon which many extracellular
and intracellular signals converge to fine-tune and enhance TGF-β's effects during fibrogenesis (259) (see sect. vD). TGF-β also stimulates the production of other matrix components including cellular fibronectin and proteoglycans (198). In addition to a major role for Smad proteins, TGF-β1 stimulates collagen in stellate cells through a hydrogen peroxide- and C/EBPβ-dependent mechanism (189). The response of Smads in stellate cells differs between acute and chronic injury to further favor matrix production (128, 357, 628).

As mentioned above, lipid peroxidation products are emerging as important stimuli to extracellular matrix production (625). Their effects may be amplified by loss of antioxidant capacity of stellate cells as they activate (see sect. vG) (696). These important insights have provided the rationale for the evaluation of antioxidants in the treatment of a variety of liver diseases.

Connective tissue growth factor (CTGF/CCN2) is also a potent fibrogenic signal toward stellate cells (185, 475, 476, 507) and may be specifically upregulated by hyperglycemia and hyperinsulinemia (477). While stimulation of CTGF production has traditionally been considered TGF-β dependent (217), the possibility of TGF-β-independent regulation is increasingly likely (73).

D) CONTRACTILITY. Contractility of stellate cells may be a major determinant of early and late increases in portal resistance during liver fibrosis. The collagenous bands typical of end-stage cirrhosis contain large numbers of activated stellate cells (534, 536, 537). These impede portal blood flow by constricting individual sinusoids and by contracting the cirrhotic liver. The acquisition of a contractile phenotype during stellate cell activation has been documented in culture and in vivo and is mediated in part by receptors that interact with the extracellular matrix and are driven by calcium signaling (413). As noted in section vD, endothelin-1 and nitric oxide are major counterregulators controlling stellate cell contractility, in addition to a growing list of additional mediators including angiotensinogen II, eicosanoids, atrial natriuretic peptide, somatostatin, and carbon monoxide, among others (see Refs. 525, 534, 536, 537 for reviews). While most studies implicates calcium signaling in response to endothelin-1-induced contractility (490), a recent study contradicts that view by demonstrating calcium-independent contractile force in stellate cells (413).

As stellate cells activate, the expression of the cytoskeletal protein α-SMA is increased (514, 538), which confers increased contractile potential. More extensive descriptions of α-SMA and other contractile filaments are reviewed above and in several reports (192, 448, 525, 546, 661). While the conventional wisdom is that α-actin expression enhances tissue fibrosis, mice lacking this protein in myofibroblasts have increased renal fibrosis in experimental glomerulonephritis (633), suggesting that α-actin induction may be a counterregulatory response to enhanced fibrogenesis by myofibroblasts, including activated stellate cells.

E) MATRIX DEGRADATION. Fibrosis reflects a balance between matrix production and degradation. The degradation of extracellular matrix is a key event in hepatic fibrosis. Early disruption of the normal hepatic matrix by matrix-degrading proteases hastens its replacement by scar matrix, which has deleterious effects on cell function. Disruption of the normal liver matrix is also a requirement for tumor invasion and desmoplasia (15) and may be particularly relevant to pancreatic stellate cells (466). Degradation in these contexts is referred to as being "pathological." On the other hand, resorption of excess matrix in patients with chronic liver disease provides the opportunity to reverse hepatic dysfunction and portal hypertension.

An understanding of mechanisms involved in matrix remodeling has evolved significantly in the past several years. A critical element in matrix remodeling is a family of matrix-metalloproteinases (also known as matrixins). These are calcium-dependent enzymes that specifically degrade collagens and noncollagenous substrates (16, 50, 262). As a general rule, the matrix-metalloproteinases fall into five categories based upon their substrate specificity: 1) interstitial collagens (MMP-1, -8, -13), 2) gelatinases (MMP-2, -9, and fibroblast activation protein), 3) stromelysins (MMP-3, -7, -10, -11), 4) membrane type (MMP-14, -15, -16, -17, -24, -25), and 5) metalloelastase (MMP-12).

Stellate cells are the principal source of MMP-2 (18, 420), MMP-9 (226), MMP-13 (the rodent equivalent of MMP-1) (567), and stromelysin (673). Activation of latent MMP-2 may require interaction with hepatocytes (639, 640). Markedly increased expression of MMP-2 is characteristic of cirrhosis (51). MMP-9 may also be secreted by stellate cells (225, 227).

A major determinant of progressive fibrosis is failure to degrade the increased interstitial or scar matrix. Matrix metalloproteinase-1 (MMP-1) is the main protease that can degrade type I collagen, the principal collagen in fibrotic liver. Sources of this enzyme are not as clearly established as for the type IV collagenases. Stellate cells express MMP-1 mRNA, but little enzyme can be detected (420).

Regulation of matrix metalloproteinase activity occurs at many levels, among which is their inactivation by binding to tissue inhibitors of metalloproteinases (TIMPs) (262). Stellate cells also produce functional TIMP-1 and TIMP-2 (17), and sustained production of these proteins during liver injury could inhibit the activity of interstitial collagenases, leading to reduced degradation of the accumulating matrix during liver injury. TIMP-1 also is antiapoptotic towards stellate cells (429), and thus its sustained expression in liver injury will enlarge the population of activated stellate cells by preventing their clearance. In support of TIMP's role in vivo, transgenic
overexpression of TIMP-1 in liver, or administration of TIMP neutralizing antibodies, both delay regression of liver fibrosis in experimental animals (721).

Stellate cells express uroplasminogen activator receptor (uPA-R) and its inhibitor (PAI-1), as well as other components of the plasmin system (152, 154, 255, 320, 348, 731). These findings suggest that stellate cells contain most, if not all, of the molecules necessary to either activate or inhibit metalloproteinases.

Most recently, increased proteolytic activity ascribed to a disintegrin and metalloproteinase with thrombospondin type repeats (ADAMS)-13 has been reported in activated stellate cells (447). However, the native substrate(s) and biological role of this protease is not known.

F) RETINOID LOSS (SEE SECT. IIA). Activation of stellate cells is accompanied by the loss of the characteristic perinuclear retinoid (vitamin A) droplets. In culture, retinoid is stored as retinyl esters, whereas the form of retinoid released outside the cell during activation is retinol, suggesting that there is intracellular hydrolysis of esters prior to export (175). Whether retinoid loss is required for stellate cells to activate, and which retinoids might accelerate or prevent activation are not clarified.

3. Resolution

As attention has turned to the treatment of liver fibrosis, the issue of how stellate cell activation resolves has become quite critical (147, 169, 170, 262). Two potential pathways account for reduction in activated stellate cells, either reversion to a quiescent phenotype or clearance through apoptosis. Although reversion can be accomplished in cultured stellate cells through transfer of activated cells to a basement membrane matrix (181, 462), this has not been validated in vivo. To do so, genetic lineage tracing would be required to confirm that cells once activated have resumed a quiescent phenotype; however, such studies have not yet been reported.

In contrast, a large amount of evidence supports the importance of stellate cell apoptosis during regression of liver fibrosis (262, 264). In culture, stellate cells are sensitive to CD95-L and TRAIL-mediated apoptosis, and NK cells can induce apoptosis of stellate cells by a TRAIL-mediated mechanism (510) (see sect. vC). NGF derived from hepatocytes is also apoptotic towards stellate cells (454) and is antagonized by serotonin receptor signaling (554). Apoptosis requires an intact proteosomal degradational pathway, since its inhibition prevents stellate cell apoptosis (6). In a recent study (510), an antifibrotic effect of NK cells was indicated by the presence of increased fibrosis in mice depleted of NK cells by anti-asialo-GM1 antibody and by decreased fibrosis after NK cell activation by a TLR3 ligand poly I:C. The NK cell-induced stellate cell apoptosis was specific for activated stellate cells that expressed the NK cell activating receptor NKGD.

The activated NK cells deliver a lethal blow to stellate cells by inducing apoptosis with TRAIL. In this study, NK cell function was dependent on interferon-γ and provided an explanation for earlier experiments demonstrating an important antifibrotic role for interferon-γ (541). The antifibrotic role of NK cells was further supported by evidence of their direct adhesion to stellate cells in mouse livers, and by the development of greater fibrosis in mice genetically deficient in NK cells (412). Most recently, these findings have been reinforced by studies in humans with HCV (424). In addition to NK cells, activated Kupffer cells can also provoke stellate cell apoptosis by a unique caspase 9- and a receptor-interacting protein-dependent mechanism (158).

The antifibrotic role of NK cells is also consistent with the clinical data of increased liver fibrosis in the setting of therapeutic immunosuppression. The effect of single immunosuppressive agents on NK cell function is minimal, but the combination of cyclosporine and corticosteroids results in a significant loss of NK cell cytotoxicity (246). In addition, cyclosporine renders some cells resistant to NK cell-mediated cytotoxicity. The effect of HIV infection on NK cell number and function is more complex. Some NK cell subsets coexpress CD4 and HIV coreceptors and are targets for infection with HIV. NK cells from HIV-infected patients have reduced cytolytic activity and decreased production of cytokines (149). The hypothesis that NK cells limit liver fibrosis by inducing stellate cell apoptosis predicts that NK cell function will be relatively impaired in individuals with rapid progression of fibrosis compared with those in whom liver fibrosis progresses slowly. It may also explain why fibrosis accelerates with aging (502), since NK cell function declines with age.

B. Transcriptional Regulation of Stellate Cell Behavior

Evolving concepts of transcriptional gene regulation have now been applied to stellate cell biology and fibrosis (see Fig. 8). Both genetic and epigenetic regulation are critical to stellate cell responses and are reviewed extensively in several recent articles (141, 379, 380, 529, 594, 654). In addition, evidence of posttranscriptional control has been described in stellate cells as well (355).

Stellate cell activation may result from either "activating" events, such as induction of transcription factor splice forms, as well as loss of repressive signaling. These complex cascades illustrate how transcriptional regulation in stellate cells is finely tuned and involves several interdependent layers of both transcriptional, translational, posttranslational, and epigenetic control. In addition, the identification of microRNAs has emerged as a major new pathway of gene regulation in many systems.
including cancer (662); however, this area has not yet been explored in stellate cells.

A growing number of transcription factors have been identified in stellate cells, yet these only represent a small number of the total number of factors contributing to transcriptional control (see Table 2). Many target genes of these transcription factors in stellate cells have been reported, but those target genes most intensively evaluated have included type I collagen (α1- and α2-chains), TGF-β1 and TGF-β receptors, MMP-2, TIMPs 1 and 2, and α-SMA (141, 379, 380, 529, 594, 654).

The following four examples illustrate how stellate cell activation may be controlled by widely divergent regulatory pathways, including transcription factors that contribute to stellate cell activation directly and whose deletion attenuates fibrosis (e.g., Foxf1 and JunD), alternative splicing of a growth inhibitory transcription factor (e.g., KLF6), epigenetic regulation of a factor regulating stellate cell survival (e.g., NFκB), and regulation of a transcription factor whose expression maintains stellate cell quiescence (e.g., Lhx2).

1. Foxf1 and JunD

The requirement for “activating” transcription factors is the most direct transcriptional pathway to provoke stellate cell activation. As discussed in section vA, Foxf1 expression contributes to the activation of stellate cells, and deletion of one Foxf1 allele reduces stellate cell activation and fibrosis (280). A remarkably similar story has emerged about JunD, which is a member of the AP-1 transcription factor complex (276). Studies initially performed in cultured stellate cells identified JunD as a transcriptional regulator of TIMP-1 (609), a molecule whose sustained expression in injured liver contributes to stellate cell survival and inhibition of matrix degradation.

More recently, this finding has been complemented by evidence that JunD knockout mice are protected from CCl4-induced hepatic fibrosis, associated with reduced numbers of activated stellate cells and diminished expression of hepatic TIMP-1 (608). Moreover, stellate cells isolated from these JunD −/− animals have reduced TIMP-1 expression, whereas the activation of JunD in wild-type cells requires ERK-dependent phosphorylation of a specific serine residue (Ser-100) (608).

2. KLF6

Several years ago we employed subtractive hybridization cloning to isolate cDNAs upregulated during early stellate cell activation in vivo (335). Among these was a novel zinc finger transcription factor, which was initially termed “Zf9” and is now called “Kruppel-like factor 6 (KLF6)” that is rapidly induced as an immediate-early gene during stellate cell activation in vivo and in culture is a member of a growing family of related zinc finger transcription factors that share identical C2H2 COOH-terminal DNA binding domains (54). Because KLF6 was induced during stellate cell activation, we assumed that it stimulated this process and identified a number of relevant transcriptional targets including TGF-β1 and its receptors (306), urokinase type plasminogen activator (70, 615). Subsequently, we identified KLF6 as a growth inhibitory protein that functions as a tumor suppressor gene that inactivated a number of cancers including prostate (439), colon (521), and hepatocellular carcinoma (327). These findings were paradoxical to our initial studies in that they contradicted the presumption that KLF6 is
growth promoting in stellate cells. The paradox may have been resolved with the discovery that KLF6 is alternatively spliced (437, 438) and that growth-promoting short forms, rather than full-length isoforms, are overexpressed during stellate cell activation. This observation is currently being further evaluated with attempts to identify stimuli that drive alternative splicing of stellate cells during injury responses and cancer.

3. Epigenetic regulation of NFκB activity

Methylation of CpG islands in upstream regulatory regions typically leads to gene repression. Elegant studies by Mann and colleagues (140, 380, 452, 453) have demonstrated induction during stellate cell activation of two key molecules contributing to methylation of CpG islands, the repressors CBF1 and MeCP2. These molecules critically regulate expression of IκB, the major NFκB repressor complex. When stellate cells are quiescent, CBF1 and MeCP2 are low, and thus transcription of the IκB gene is high. The net effect is strong inhibition of NFκB activity, leading to stellate cell apoptosis and decreased fibrogenesis. In contrast, when CBF1 and MeCP2 are high, IκB is repressed and NFκB activity is disinhibited or increased, which promotes stellate cell survival and therefore increased fibrosis. This finding has been exploited by demonstrating that sulfasalazine, a commonly used anti-inflammatory drug indicated for treatment of inflammatory bowel disease, inhibits the kinase (IKK) that activates IκB. Based on the findings in isolated stellate cells, sulfasalazine and related compounds accelerate recovery from experimental fibrosis by clearance of activated stellate cells through apoptosis (223, 453). Since these activated cells typically express high levels of TIMP-1, a metalloproteinase inhibitor, their clearance leads to increased net activity of matrix degrading proteases.

4. Lhx2

This LIM homeodomain protein had been explored primarily for its role in neural and hematopoietic differentiation (500) before its significance to stellate cell activation was uncovered. Initial analysis of the Lhx2 knockout mouse revealed that late fetal demise was due to loss of hematopoiesis in liver (500). Subsequently, Carlsson and colleagues (683) recognized that the liver phenotype was due to excessive accumulation of extracellular matrix (ECM) in these Lhx2 −/− livers. Indeed, stellate cells in these livers are highly activated and account for this ECM accumulation, and overexpression of Lhx2 in normal cultured stellate cells also leads to decreased activation and ECM gene expression. Thus Lhx2 appears to be a transcriptional factor that preserves stellate cell quiescence, raising the interesting concept that activation of stellate cells may be a “default” pathway requiring tonic inhibition by Lhx2 and possibly related factors. Recently, the same approaches have identified a similar role for the transcription factor FoxO1, since stellate cell activation and fibrosis are amplified in cells or mice with reduced FoxO1 activity (1).

C. Paracrine Interactions With Other Resident Liver Cells

Stellate cells exist in a multicellular milieu where cell-cell interactions underlie the tightly regulated homeostatic control required for normal liver function and the response to disease. Interactions between stellate cells and inflammatory cells have been extensively reviewed in section V, but bidirectional regulatory pathways between stellate and other resident liver cells are equally important (370).
In normal liver, hepatocytes and stellate cells cooperate in retinoid metabolism where the compounds are first taken up by hepatocytes, then transferred to stellate cells for storage (see sect. I.A). In liver injury, hepatocytes are a potent source of fibrogenic lipid peroxides (366, 443, 625) and Fas-mediated apoptotic fragments (84, 85) as well as acute phase reactants (319) and plasminogen activators (731). α2-Macroglobulin generated by hepatocytes may reduce fibrogenesis by sequestering TGF-β (577). Cytokine cross-talk is equally important and includes TGF-β (58, 419), TGF-α (284), insulin-like growth factors and binding proteins (72, 211, 607), HGF (108, 305, 469, 709), VEGF (109), NGF (21, 454), CTGF (507), IL-6 (32), thrombospondin (430), as well as other paracrine factors derived from hepatic tumor cells (34, 148). Stellate cells may also support hepatocyte function ex vivo, which could advance the development of liver support devices (687). There is also evidence that HCV-infected hepatocytes may release fibrogenic factors towards stellate cells (578, 647), which could explain how patients with normal serum transaminases infected with HCV can still develop hepatic fibrosis. Similarly, HCC cells expressing the HBV X protein stimulate stellate cells to produce the angiogenic molecule angiopoiteitin-2 (562). Finally, in hemochromatosis, iron-laden hepatocytes are thought to contribute to hepatic stellate cell activation (518, 519).

Stellate cell interactions with Kupffer cells were among the first paracrine interactions described among nonparenchymal cells in liver (55, 164, 168, 316, 370, 404, 405) and may be either pro- or antifibrotic. Kupffer cell infiltration typically precedes stellate cell activation in animal models of liver injury (242, 277). Release of chemoattractant mediators, for example MCP-1 or osteopontin (293), contributes to their infiltration. Kupffer cell-derived fibrogenic mediators include TGF-β (404, 405) and lipid peroxides (642). In support of their role in activating stellate cells, Kupffer cell inactivation by gadolinium chloride reduces stellate cell activation and fibrosis in animal models (530). In hemochromatosis, iron accumulation in Kupffer cells and macrophages is thought to induce stellate cell activation (346, 485). Kupffer cells may also be stimulated by apoptotic fragments to release fibrogenic mediators (82). On the other hand, Kupffer cells may stimulate stellate cell apoptosis (158). Cross-talk between stellate and Kupffer cells following exposure to LPS may also impair liver regeneration (4).

Stellate and sinusoidal endothelial cells are likely to have a common embryologic precursor. This fact, combined with their close physical proximity, makes paracrine interactions quite likely and potentially important. Controlled, coordinated release of proteases may be a critical early event in hepatic regeneration (303, 304), possibly to activate latent mitogens including HGF (396). Both cell types exhibit coordinated induction of VEGF receptors during liver injury (10). This interaction may be especially important during tumorigenesis (464). In addition, early changes in cellular fibronectin splice forms generated by sinusoidal endothelium activate hepatic stellate cells (270). Other pathways shared between these two cell types include TGF-β (58, 118), IGF-1 (117), leptin (253, 254), plasminogen (348), endothelin, and nitric oxide (533, 542, 543, 719).

Recent studies provide mounting evidence of close interactions between stellate cells and bile duct epithelium. Such a relationship might explain why activated stellate cells encircle proliferating bile ducts in cholestatic liver injury (308). In culture, secretions from bile duct epithelium induce α-SMA in perisinusoidal fibrogenic cells (330) due to stimulation by MCP-1. Most intriguing is the intimate relationship between stellate cells and bile duct cells during liver development and repair (see sect. iii) raising the possibility that stellate cells are required for differentiation of bipotential epithelial cells into biliary epithelium or even the possibility of trans-differentiation between the two cell types.

D. Behavior of Stellate Cells in Liver Disease

Involvement of stellate cells in the fibrotic response to liver injury has been recognized for several years (75, 459) (see sect. i). Stellate cell activation from a quiescent to a highly fibrogenic cell in diseased liver is characterized morphologically by enlargement of rER, diminution of vitamin A droplets, ruffled nuclear membrane, appearance of contractile filaments, and proliferation (555, 570). Cells with features of both quiescent and activated cells are often called “transitional cells.” Studies in animals have defined the time course and localization of proliferating stellate cells in different models of injury (242, 277, 378, 635). These and related studies consistently demonstrate active proliferation of stellate cells in regions of greatest injury, which is typically preceded by an influx of inflammatory cells and is associated with extracellular matrix accumulation.

The recognition of stellate cells’ importance in normal and injured liver has led to a greater appreciation of their role in many human liver diseases (401). Alcoholic liver disease is the best-studied example, with numerous reports documenting features of activation in situ (230, 244, 459). Activation of stellate cells, as assessed by expression of α-SMA, may occur in the presence of steatosis alone (520), suggesting that bland steatosis may be a precursor of hepatic fibrosis, even without apparent inflammation. Studies of viral hepatitis (201, 218, 222, 261, 298) and massive hepatic necrosis (52, 144) have confirmed morphological and immunohistological features of stellate cell activation. In hepatocellular carcinoma (143, 649) and biliary malignancy (569), activated stellate cells contribute to the accumulation of tumor stroma. These
findings are supported by animal studies suggesting that activated stellate cells contribute to hepatic metastases (464, 465), and culture studies demonstrating paracrine activation of stellate cells by tumoral cells (148). In addition, a primary benign tumor of stellate cells, spongiotic pericytoma, has been described in rats treated with carcinogens (622), as well as a malignant tumor from which the L190 stellate cell-like cell line has been derived (428). Stellate cells have been characterized in a number of other human diseases, including vascular disease (570), hematologic malignancy (570), biliary disease (570), mucopolysaccharidosis (523), acetaminophen overdose (402), and leishmaniasis (138) as well as in drug abusers (650). In addition, stellate cells have been readily identified in fibrosis and granuloma formation associated with schistosomiasis (33, 74, 100). In primary biliary cirrhosis (PBC), a slowly progressive cholestatic disease primarily in woman, large multivesicular stellate cells have been described (80), the significance of which is unclear. In PBC, these may be seen at the same time as portal fibroblasts (203), and both cell types are likely to generate fibrosis.

Stimulation of stellate cells by lipid peroxides may be important in many forms of liver fibrosis, but is particularly pertinent to diseases associated with iron overload. A role for lipid peroxides is suspected in these diseases (e.g., hemochromatosis), based on both in situ studies that show a correlation between the presence of aldehyde adducts and stellate cell collagen gene expression (43, 283, 478, 479).

Because α-SMA is a sensitive marker of activated stellate cells in situ, it is increasingly used as an early indication of fibrogenic activity in human liver disease, even before extracellular matrix accumulates. For example, two studies have used α-actin staining to predict early development of liver fibrosis in patients following liver transplantation for HCV (191, 558). Similar studies have been performed in patients with nonalcoholic fatty liver disease, which also has a variable rate of fibrosis (110, 151). The value of using α-actin staining to quantify fibrogenesis is underscored by its inclusion as a primary end point in clinical trials of antifibrotics in HCV refractory to antiviral therapies (http://clinicaltrials.gov/ct/show/NCT00244751?order=9).

VII. UNANSWERED QUESTIONS AND FUTURE DIRECTIONS

The unfolding mysteries of the hepatic stellate cell and the breadth of its protean features have far exceeded anyone’s imagination when the cell was first isolated over 20 years ago. With that in mind, it is difficult to predict what additional surprises will emerge from ongoing study of this fascinating cell type. Nonetheless, some key issues are likely to challenge current and future investigators. In particular, the stellate cells’ pleuripotency and roles in both liver development and regeneration merit intense evaluation and await the development of better genetic models to confirm these prospects. Continued elucidation of the stellate cell’s immune functions is very important, in particular its contribution to the unusually high immunotolerance of liver, as well as its potential role in viral infection (including HIV), graft versus host disease, and fibrogenesis. More evidence of subtle and complex cross-talk between stellate cells and inflammatory cell subsets is sure to emerge. The myriad, intersecting pathways of hepatic stellate cell activation will continue to yield new paradigms relevant to tissue repair in other organs as well. We still await evidence that activated stellate cells can revert to a more quiescent state in vivo, which will require sophisticated genetic models but could provide further evidence of the cell’s remarkable plasticity. The use of stellate cells to support hepatocellular differentiation in culture and hepatocyte engraftment in vivo are also promising new roles. Based on these findings, the potential use of stellate cells in liver assist devices merits further study and could create new prospects for patients with end-stage liver disease. One thing is certain, stellate cells will continue to fascinate, engage, and excite liver biologists, immunologists, and clinicians for the foreseeable future.

ACKNOWLEDGMENTS

I acknowledge the helpful comments of Drs. Axel Gressner, Ralf Weiskirchen, Yutaka Inagaki, Hitoshi Yoshiji, Derek Mann, Hal Yee, and Ramon Bataller.

Address for reprint requests and other correspondence: S. L. Friedman, Div. of Liver Diseases, Box 1123, Mount Sinai School of Medicine, 1425 Madison Ave., Rm. 11–70C, New York, NY 10029-6574 (e-mail: Scott.Friedman@mssm.edu).

GRANTS

The author’s research is supported by National Institute of Diabetes and Digestive and Kidney Diseases Grants DK-37340 and DK-56621, the Feld Foundation, and the United States-Israel Binational Science Foundation.

REFERENCES


HEPATIC STELLATE CELLS

155


91. Chan ES, Montesinos MC, Fernandez P, Desai A, Delano DL, Delaney JL, Wisse E, Geerts A. Insulin-like growth factor-II/mannose 6-phosphate receptor expression in hepatic Ito cells: a role in the hepatocyte glucose transport mechanisms regulating intracellular pH in hepatic stel-


112. Di Sario A, Baroni GS, Bendia E, D’Ambrosio L, Ridolfi F, Marileo JR, Jezequel AM, Benedetti A. Characterization of ion transport mechanisms regulating intracellular pH in hepatic stel-


HEPATIC STELLATE CELLS


HEPATIC STELLATE CELLS

310. Kordes C, Sawitza I, Muller-Marbach A, Ale-Agha N, Keitel V, Klonsowski-Stumpe H, Haussinger D. CD133(+) hepatic stellate...


437. Nieto N, Friedman SL, Cederbaum AI. Cytochrome P450 2E1-derived reactive oxygen species mediate paracrine stimulation of
Hepatic stellate cells

165


447. Niiya M, Uemura M, Zheng XW, Pollak ES, Dockal M, Schei


525. Reeves HL, Brenner DA.
523. Reeves HL, Burt AD, Wood S, Day CP.
520. Reeves HL, Burt AD, Wood S, Day CP.


Hepatic Stellate Cells


